Original Article
Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction
N Engl J Med 2001; 345:725-730September 6, 2001
- Abstract
Background
Surgical resection of adenocarcinoma of the stomach is curative in less than 40 percent of cases. We investigated the effect of surgery plus postoperative (adjuvant) chemoradiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesophageal junction.
Methods
A total of 556 patients with resected adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to surgery plus postoperative chemoradiotherapy or surgery alone. The adjuvant treatment consisted of 425 mg of fluorouracil per square meter of body-surface area per day, plus 20 mg of leucovorin per square meter per day, for five days, followed by 4500 cGy of radiation at 180 cGy per day, given five days per week for five weeks, with modified doses of fluorouracil and leucovorin on the first four and the last three days of radiotherapy. One month after the completion of radiotherapy, two five-day cycles of fluorouracil (425 mg per square meter per day) plus leucovorin (20 mg per square meter per day) were given one month apart.
Results
The median overall survival in the surgery-only group was 27 months, as compared with 36 months in the chemoradiotherapy group; the hazard ratio for death was 1.35 (95 percent confidence interval, 1.09 to 1.66; P=0.005). The hazard ratio for relapse was 1.52 (95 percent confidence interval, 1.23 to 1.86; P<0.001). Three patients (1 percent) died from toxic effects of the chemoradiotherapy; grade 3 toxic effects occurred in 41 percent of the patients in the chemoradiotherapy group, and grade 4 toxic effects occurred in 32 percent.
Conclusions
Postoperative chemoradiotherapy should be considered for all patients at high risk for recurrence of adenocarcinoma of the stomach or gastroesophageal junction who have undergone curative resection.
Media in This Article
Figure 2
Relapse-free Survival among All Eligible Patients, According to Treatment-Group Assignments.Figure 1
Overall Survival among All Eligible Patients, According to Treatment-Group Assignment.Article Activity
- Article
The curative treatment of stomach cancer requires gastric resection.1 However, most patients are not cured by this surgery. A review of data from the National Cancer Data Base on 50,169 patients in the United States who underwent gastrectomy between 1985 and 1996 found a 10-year survival rate of 65 percent among patients with stage IA disease (tumor confined to the gastric mucosa), but the 10-year survival rates among those with more advanced disease ranged from 3 percent to 42 percent, depending on the extent of disease.2
The high rate of relapse after resection makes it important to consider adjuvant treatment for patients with stomach cancer. However, adjuvant chemotherapy has not resulted in higher survival rates than surgery alone.3-5
Local or regional recurrence in the gastric or tumor bed, the anastomosis, or regional lymph nodes occurs in 40 to 65 percent of patients after gastric resection with curative intent.6-9 The frequency of such relapses makes regional radiation an attractive possibility for adjuvant therapy. A phase 3 trial10 found clinically limited but statistically significant improvement (P=0.009) in survival after preoperative regional radiotherapy in patients with cancer of the gastric cardia. Small phase 3 trials have suggested that survival is improved after postoperative radiation, with or without fluorouracil,11 and after intraoperative radiation.12
Phase 3 trials have found that 12 to 20 percent of patients with residual or locally unresectable gastric cancer are long-term survivors after treatment with radiation plus fluorouracil.13,14 We undertook a study to determine the efficacy of chemoradiotherapy in patients with resected gastric cancer. The trial was initiated in 1991 to compare surgery followed by fluorouracil plus irradiation of the gastric bed and regional lymph nodes with surgery alone.
Methods
Eligibility
The eligibility criteria included histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction; complete resection of the neoplasm, defined as resection performed with curative intent and resulting in resection of all tumor with the margins of the resection testing negative for carcinoma; a classification of the resected adenocarcinoma of the stomach or gastroesophageal junction as stage IB through IVM0 according to the 1988 staging criteria of the American Joint Commission on Cancer15; a performance status of 2 or lower according to the criteria of the Southwest Oncology Group; adequate function of major organs (indicated by a creatinine concentration no more than 25 percent higher than the upper limit of normal; a hemogram within the normal limits; a bilirubin concentration no more than 50 percent higher than the upper limit of normal; a serum aspartate aminotransferase concentration no more than five times the upper limit of normal; and an alkaline phosphatase concentration no more than five times the upper limit of normal); a caloric intake greater than 1500 kcal per day by oral or enterostomal alimentation; registration between 20 and 41 days after surgery, with treatment beginning within 7 working days after registration; and the provision of written informed consent according to institutional and federal guidelines. When a patient was registered, surgeons and pathologists from the Southwest Oncology Group reviewed the patient's surgery and pathology reports to confirm the completeness of the resection.
Treatment Plan
After undergoing gastrectomy, patients were randomly assigned to surgery alone or to the postoperative combination of fluorouracil plus leucovorin and local–regional radiation. Randomization was performed 20 to 40 days after surgery by means of a dynamic balancing procedure that included stratification according to the tumor stage (T1 to T2, T3, or T4) and the nodal status (no positive nodes, one to three positive nodes, or four or more positive nodes).
The regimen of fluorouracil and leucovorin was developed by the North Central Cancer Treatment Group16 and was administered before and after radiation. Chemotherapy (fluorouracil, 425 mg per square meter of body-surface area per day, and leucovorin, 20 mg per square meter per day, for 5 days) was initiated on day 1 and was followed by chemoradiotherapy beginning 28 days after the start of the initial cycle of chemotherapy. Chemoradiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, with fluorouracil (400 mg per square meter per day) and leucovorin (20 mg per square meter per day) on the first four and the last three days of radiotherapy. One month after the completion of radiotherapy, two five-day cycles of fluorouracil (425 mg per square meter per day) plus leucovorin (20 mg per square meter per day) were given one month apart. The dose of fluorouracil was reduced in patients who had grade 3 or 4 toxic effects.
The 4500 cGy of radiation was delivered in 25 fractions, five days per week, to the tumor bed, to the regional nodes, and 2 cm beyond the proximal and distal margins of resection. The tumor bed was defined by preoperative computed tomographic (CT) imaging, barium roentgenography, and in some instances, surgical clips. The presence of proximal T3 lesions necessitated treatment of the medial left hemidiaphragm. We used the definitions of the Japanese Research Society for Gastric Cancer for the delineation of the regional-lymph-node areas.17,18 Perigastric, celiac, local para-aortic, splenic, hepatoduodenal or hepatic-portal, and pancreaticoduodenal lymph nodes were included in the radiation fields. In patients with tumors of the gastroesophageal junction, paracardial and paraesophageal lymph nodes were included in the radiation fields, but pancreaticoduodenal radiation was not required. Exclusion of the splenic nodes was allowed in patients with antral lesions if it was necessary to spare the left kidney. Radiation was delivered with at least 4-MV photons. Doses were limited so that less than 60 percent of the hepatic volume was exposed to more than 3000 cGy of radiation. The equivalent of at least two thirds of one kidney was spared from the field of radiation, and no portion of the heart representing 30 percent of the cardiac volume received more than 4000 cGy of radiation. Fluorouracil (400 mg per square meter) and leucovorin (20 mg per square meter) were administered as an intravenous bolus on each of the first four days and the last three days of irradiation. This regimen was shown to be tolerable in a previous trial.19
Quality Assurance for Radiotherapy
Prior approval of the treatment plan for radiotherapy by the radiation-oncology coordinator was required before the initiation of radiotherapy. Treatment fields, dosimetry, surgery and pathology reports, and preoperative tumor imaging were submitted for review before treatment began. Plans that were not approved because of the risk of toxic effects on critical organs or the failure to treat the appropriate target volumes were corrected before therapy was begun. At these reviews, 35 percent of the treatment plans were found to contain major or minor deviations from the protocol, most of which were corrected before the start of radiotherapy. A final quality-assurance review of radiotherapy (conducted after the delivery of radiation) revealed major deviations in 6.5 percent of the treatment plans.
Follow-up of Patients
Follow-up of both groups occurred at three-month intervals for two years, then at six-month intervals for three years, and yearly thereafter. Follow-up consisted of physical examination, a complete blood count, liver-function testing, chest radiography, and CT scanning as clinically indicated. The site and date of the first relapse and the date of death, if the patient died, were recorded.
Statistical Analysis
Our study was originally designed to include 350 patients. With a two-sided alpha level of 0.05, the study had an estimated 80 percent power to detect a 50 percent relative difference in survival (equivalent to a hazard ratio for death of 1.5) and an estimated 95 percent power to detect a 60 percent relative difference in relapse-free survival (a hazard ratio for death or relapse of 1.6). However, since enrollment was higher than expected, the data and safety monitoring committee approved an amendment to expand the enrollment to 550 eligible patients, which ensured 90 percent power to detect a 40 percent difference in survival (a hazard ratio of 1.4) and a 40 percent difference in relapse-free survival.
The two stratification factors, the T stage (three levels) and the N stage (three levels), were included as covariates in the Cox regression analysis.20 The examination of other potential covariates (age, race, the extent [D level] of the dissection, and the location of the primary tumor) yielded no significant effects, and these variables were not included in the analysis. All eligible patients were included in the analyses of survival and relapse-free survival according to the intention-to-treat principle.
The sites of relapse were classified as follows: the relapse was coded as local if tumor was detected in the surgical anastomosis, residual stomach, or gastric bed, as regional if tumor was detected in the peritoneal cavity (including the liver, intraabdominal lymph nodes, and peritoneum), and as distant if the metastases were outside the peritoneal cavity. All eligible patients in the chemoradiotherapy group who received any treatment were included in the analysis of toxic effects.
The study was monitored by the data and safety monitoring committee of the Southwest Oncology Group. At two planned interim analyses, the committee assessed whether the trial could be terminated early according to protocol-specified guidelines. Both interim analyses resulted in the continuation of the study until the planned time for the reporting of final data.
Results
Demographic Characteristics
Between August 1, 1991, and July 15, 1998, 603 patients were registered. Forty-seven patients (8 percent) were deemed ineligible because they had positive surgical margins, had disease other than adenocarcinoma on pathological examination, or were registered after the specified time limit. Of the remaining 556 patients, 275 were randomly assigned to surgery only and 281 to surgery plus chemoradiotherapy. Demographic factors (Table 1Table 1
Characteristics of the Patients and the Tumors.) were similar between the two groups; 94 percent of the patients were ambulatory or asymptomatic after surgery.Most tumors were in the distal stomach. Lesions were present in the gastroesophageal junction in approximately 20 percent of the patients. The patients were at high risk for relapse; more than two thirds of them had stage T3 or T4 tumors, and 85 percent had nodal metastases (Table 1).
Treatment
Of the 281 patients assigned to the chemoradiotherapy group, 181 (64 percent) completed treatment as planned (Table 2Table 2
Reasons for the Cessation of Chemoradiotherapy among the 281 Patients in the Chemoradiotherapy Group.); 17 percent stopped treatment because of toxic effects (investigators were not required to indicate the specific toxic effect that prompted the cessation of treatment). Eight percent declined treatment, 5 percent had progression of disease while receiving treatment, 1 percent died during the course of treatment, and 4 percent discontinued treatment for other reasons. Twelve patients (eight assigned to receive chemoradiotherapy and four assigned to receive surgery only) declined to continue the assigned therapy but are included in the assigned study group according to the intention to treat. The eight patients who declined to receive the protocol-specified chemoradiotherapy could not be evaluated for toxic effects.Surgical Procedures
The only surgery-related requirements for eligibility were resection with curative intent and en bloc resection of the tumor with negative margins. Also required was a statement from the operating surgeon that no metastatic or unresected adenocarcinoma was present. Gastric resection with an extensive (D2) lymph-node dissection was recommended. This procedure entails the resection of all perigastric lymph nodes and some celiac, splenic or splenic-hilar, hepatic-artery, and cardial lymph nodes, depending on the location of the tumor in the stomach.17 However, since patients were usually identified postoperatively, we could not require specific surgical procedures. The operating surgeon completed a form defining the extent of lymphadenectomy. Of 552 patients whose surgical records were reviewed for completeness of resection, only 54 (10 percent) had undergone a formal D2 dissection. A D1 dissection (removal of all invaded [N1] lymph nodes) had been performed in 199 patients (36 percent), but most patients (54 percent) had undergone a D0 dissection, which is less than a complete dissection of the N1 nodes.
Toxicity
The toxic effects classified as grade 3 or higher that occurred among the 273 patients who received postoperative chemoradiotherapy are summarized in Table 3Table 3
Major Toxic Effects of Chemoradiotherapy.. Hematologic and gastrointestinal toxic effects predominated. The most common hematologic toxic effect was leukopenia. Severe thrombocytopenia was uncommon. Gastrointestinal toxic effects included nausea, vomiting, and diarrhea. Other types of toxic effects occurred in less than 10 percent of the patients. Three patients (1 percent) died as a result of a toxic effect attributed to chemoradiotherapy (pulmonary fibrosis in one patient, a cardiac event in another, and sepsis complicating myelosuppression in the third).Overall and Relapse-free Survival
With a median follow-up period of 5 years, the median duration of survival was 36 months in the chemoradiotherapy group and 27 months in the surgery-only group (Figure 1Figure 1
Overall Survival among All Eligible Patients, According to Treatment-Group Assignment.). The three-year survival rates were 50 percent in the chemoradiotherapy group and 41 percent in the surgery-only group. The hazard ratio for death in the surgery-only group, as compared with the chemoradiotherapy group, was 1.35 (95 percent confidence interval, 1.09 to 1.66; P=0.005).The hazard ratio for relapse in the surgery-only group, as compared with the chemoradiotherapy group, was 1.52 (95 percent confidence interval, 1.23 to 1.86; P<0.001). The median duration of relapse-free survival was 30 months in the chemoradiotherapy group and 19 months in the surgery-only group (Figure 2Figure 2
Relapse-free Survival among All Eligible Patients, According to Treatment-Group Assignments.). The three-year rates of relapse-free survival were 48 percent in the chemoradiotherapy group and 31 percent in the surgery-only group. Relapses were reported in 64 percent of the patients in the surgery-only group and 43 percent of those in the chemoradiotherapy group.We recorded information on the site of the first relapse only, and these sites were categorized as local, regional, or distant (Table 4Table 4
Sites of Relapse.). Local recurrence occurred in 29 percent of the patients in the surgery-only group and 19 percent of those in the chemoradiotherapy group. Regional relapse — typically, abdominal carcinomatosis — was reported in 72 percent of those in the surgery-only group and 65 percent of those in the chemoradiotherapy group; 18 percent of those in the surgery-only group and 33 percent of those in the chemoradiotherapy group had distant relapses. Because we only required documentation of a single site of first relapse, a statistical assessment of differences in these patterns of relapse rates would be biased by a lack of complete reporting of sites.We were unable to detect differences in the effects of treatment according to sex, race, the location of the primary tumor, or the extent of the surgical procedure.
Discussion
In patients with rectal carcinoma,21 adenocarcinoma of the pancreas,22 and incompletely resected stomach cancer,13,14 postoperative regional radiation plus chemotherapy reduces the risk of relapse and prolongs survival. The frequent occurrence of local and regional relapses after resection for gastric cancer provided the rationale for our evaluation of the combination of chemotherapy and radiation in patients with adenocarcinoma of the stomach or gastroesophageal junction. Our results demonstrate that chemoradiotherapy after resection for gastric cancer significantly improves relapse-free and overall survival among such patients. The apparent benefit of adjuvant therapy could not be the result of shorter-than-expected survival in the surgery-only group, since the duration of survival in this group closely approximated that observed in other studies.4,23
The adequacy of surgical resection in our patients is an important issue. Resection of all detectable disease was required for participation in the trial. An extensive (D2) lymph-node dissection was recommended, but patients were not excluded on the basis of the extent of lymphadenectomy. Only 10 percent of the patients underwent a D2 dissection, 36 percent had a D1 dissection, and 54 percent had a D0 lymphadenectomy (a resection in which not all of the N1 nodes were removed).
Although one would intuitively expect extensive nodal dissection to be beneficial in removing subclinical cancer, its value has been the subject of serious debate in surgical oncology.24 Three randomized studies25-27 have compared D1 dissection with D2 dissection. The two largest of these studies26,27 found similar five-year survival rates after D1 and D2 procedures: 35 percent and 33 percent, respectively, in a study conducted in the United Kingdom and 45 percent and 47 percent, respectively, in a trial in the Netherlands. Both trials found significantly increased in-hospital mortality related to the distal pancreatectomy and splenectomy performed as part of the D2 procedure. Although these trials had their limitations — they did not control surgical technique precisely and had high overall mortality rates — no phase 3 trial to date has demonstrated a survival benefit resulting from D2 nodal resection. In our study, we were unable to detect any significant difference in relapse-free or overall survival according to the extent of the dissection (P=0.80).
In summary, our results demonstrate that local–regional radiotherapy plus fluorinated pyrimidine–based chemotherapy administered as adjuvant (postoperative) treatment significantly improves overall and relapse-free survival among patients with gastric cancer. Although this therapy may be delivered safely, radiation oncologists must be familiar with the proper techniques for the delivery of upper abdominal radiation in patients who have undergone gastrectomy, and the maintenance of adequate nutrition during therapy is essential. This study also indicates that a D0 lymphadenectomy is the most common type of lymph-node dissection performed in the United States during resection for gastric cancer. Adjuvant treatment with fluorouracil plus leucovorin and radiation should be considered for all patients with high-risk gastric cancer.
Supported in part by the following Public Health Service Cooperative Agreement grants from the National Cancer Institute: CA38926, CA32102, CA35176, CA96429, CA15488, CA21661, CA25224, CA22433, CA04919, CA46441, CA20319, CA58348, CA46113, CA27057, CA45450, CA58882, CA46368, CA63844, CA04920, CA37981, CA58686, CA12644, CA42777, CA58416, CA46136, CA74647, CA76447, CA45461, CA45807, CA45377, CA58723, CA35176, CA63845, CA16385, CA52654, CA58415, CA35281, CA35192, CA76448, CA35261, CA67663, CA46282, CA12213, and CA31946.
Source Information
From the St. Vincent's Comprehensive Cancer Center, New York (J.S.M.); the Kansas City Community Clinical Oncology Program, Kansas City, Mo. (S.R.S.); the Southwest Oncology Group Statistical Center, Seattle (J.B.); the University of Hawaii, Honolulu (S.A.H.); the University of Illinois College of Medicine, Peoria (N.C.E.); the University of Cincinnati Medical Center, Cincinnati (G.N.S.); the University of Pennsylvania Cancer Center, Philadelphia (D.G.H.); the M.D. Anderson Cancer Center, Houston (J.A.A.); the Mayo Clinic, Rochester, Minn. (L.L.G., J.A.M.); and the University of Texas at San Antonio, San Antonio (J.M.J.).
Address reprint requests to the Publications Office, Southwest Oncology Group (SWOG-9008), Operations Office, 14980 Omicron Dr., San Antonio, TX 78245-3217.
- References
References
1
Dupont JB Jr ,Lee JR ,Burton GR ,Cohn I Jr . Adenocarcinoma of the stomach: review of 1,497 cases. Cancer 1978;41:941-947
CrossRef | Web of Science | Medline2
Hundahl SA ,Phillips JL ,Menck HR . The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the “different disease“ hypothesis. Cancer 2000;88:921-932
CrossRef | Web of Science | Medline3
Gunderson LL, Donohue JH, Burch PA. Stomach. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical oncology. New York: Churchill Livingstone, 1995:1209-41.
4
Hermans J ,Bonenkamp JJ ,Boon MC , et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-1447
Web of Science | Medline5
Earle CC ,Maroun JA . Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059-1064
CrossRef | Web of Science | Medline6
Landry J ,Tepper JE ,Wood WC ,Moulton EO ,Koerner F ,Sullinger J . Patterns of failure following curative resection of gastric cancer. Int J Radiat Oncol Biol Phys 1990;191:1357-13627
Gunderson LL ,Sosin H . Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look): clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11
Web of Science | Medline8
McNeer G ,VandenBerg H Jr ,Donn FY ,Bowden L . A critical evaluation of subtotal gastrectomy for the cure of cancer of the stomach. Ann Surg 1951;134:2-7
CrossRef | Web of Science | Medline9
Thomson FB ,Robins RE . Local recurrence following subtotal resection for gastric carcinoma. Surg Gynecol Obstet 1952;95:341-344
Web of Science | Medline10
Zhang ZX ,Gu XZ ,Yin WB ,Huang GJ ,Zhang DW ,Zhang RG . Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) -- report on 370 patients. Int J Radiat Oncol Biol Phys 1998;42:929-934
CrossRef | Web of Science | Medline11
Moertel CG ,Childs DS ,O'Fallon JR ,Holbrook MA ,Schutt AJ ,Reitemeier RJ . Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984;2:1249-1254
Web of Science | Medline12
Takahashi M ,Abe M . Intra-operative radiotherapy for carcinoma of the stomach. Eur J Surg Oncol 1986;12:247-250
Web of Science | Medline13
Moertel CG ,Childs DS Jr ,Reitemeier RJ ,Colby MY Jr ,Holbrook MA . Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865-867
CrossRef | Web of Science | Medline14
A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 1982;49:1771-1777
CrossRef | Web of Science | Medline15
Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds. Manual for staging of cancer. 3rd ed. Philadelphia: J.B. Lippincott, 1988.
16
Poon MA ,O'Connell MJ ,Moertel CG , et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-1418
Web of Science | Medline17
Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. Tokyo, Japan: Kanehara, 1995.
18
van de Velde CJ ,Sasako M . Surgical treatment of gastric cancer: anatomical borders and dissection of lymph nodes. Ann Chir Gynaecol 1998;87:89-98
Medline19
Malliard JA ,Moertel CG ,Gunderson LL ,McKenna PJ . Early evaluation of 5FU plus leucovorin (LV) as a radiation enhancer for gastrointestinal carcinoma. Prog Proc Am Soc Clin Oncol 1991;10:151-151 abstract.20
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22021
Tepper JE ,O'Connell MJ ,Petroni GR , et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of Intergroup 0114. J Clin Oncol 1997;15:2030-2039
Web of Science | Medline22
Gastrointestinal Tumor Study Group
CrossRef | Web of Science | Medline23
Wanebo HJ ,Kennedy BJ ,Chmiel J ,Steele G Jr ,Winchester DP ,Osteen R . Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg 1993;218:583-592
CrossRef | Web of Science | Medline24
Hundahl SA . Gastric cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996;5:129-144
Medline25
Dent DM ,Madden MV ,Price SK . Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988;75:110-112
CrossRef | Web of Science | Medline26
Cuschieri A ,Weeden S ,Fielding J , et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999;79:1522-1530
CrossRef | Web of Science | Medline27
Bonenkamp JJ ,Hermans J ,Sasako M ,van de Velde CJH . Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-914
Full Text | Web of Science | Medline
- Citing Articles (649)
Citing Articles
1
Duk Joo Lee, Tae Sung Sohn, Do Hoon Lim, Hee Kyung Ahn, Se Hoon Park, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Dong Il Choi, Kyoung Mee Kim, Min Gew Choi, Jae Hyung Noh, Jae Moon Bae, Sung Kim, Byung Hoon Min, Won Ki Kang. (2012) Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer. Cancer Chemotherapy and Pharmacology
CrossRef2
Toshiro Okuyama, Daisuke Korenaga, Ai Edagawa, Shinji Itoh, Eiji Oki, Hirofumi Kawanaka, Yasuharu Ikeda, Yoshihiro Kakeji, Masahiro Tateishi, Shunichi Tsujitani, Kenji Takenaka, Yoshihiko Maehara. (2012) Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery. Surgery Today
CrossRef3
Peter McCulloch, Marcelo Eidi Nita, Hussain Kazi, Joaquin J Gama-Rodrigues, Karin L Dearness. 2012. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. .
CrossRef4
Vivian E. Strong. (2012) Laparoscopic Resection for Gastric Carcinoma: Western Experience. Surgical Oncology Clinics of North America 21:1, 141-158
CrossRef5
Mitsuru Sasako. (2012) Gastric Cancer Eastern Experience. Surgical Oncology Clinics of North America 21:1, 71-77
CrossRef6
Nikhil I. Khushalani. (2012) Phase I and II Clinical Trials for Gastric Cancer. Surgical Oncology Clinics of North America 21:1, 113-128
CrossRef7
Scott A. Hundahl. (2012) Surgery for Gastric Cancer: What the Trials Indicate. Surgical Oncology Clinics of North America 21:1, 79-97
CrossRef8
Ralf Metzger, Ute Warnecke-Eberz, Hakan Alakus, Fabian Kütting, Jan Brabender, Daniel Vallböhmer, Peter P. Grimminger, Stefan P. Mönig, Uta Drebber, Arnulf H. Hölscher, Elfriede Bollschweiler. (2012) Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Esophagus: ERCC1 Gene Polymorphisms for Prediction of Response and Prognosis. Journal of Gastrointestinal Surgery 16:1, 26-34
CrossRef9
K. Homayounfar, H. Becker. (2012) 7. Ausgabe der TNM-Klassifikation: Stadienverschiebung bei 60% der Magenkarzinome verändert die prognostische Aussage. Strahlentherapie und Onkologie 188:1, 96-97
CrossRef10
John V. Reynolds, Claire L. Donohoe, Erin McGillycuddy, Naraymasamy Ravi, Dermot O’Toole, Ken O’Byrne, Donal Hollywood. (2012) Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: Lessons from the experience of a high-volume center. The Journal of Thoracic and Cardiovascular Surgery
CrossRef11
Toshirou Nishida. (2012) Adjuvant therapy for gastric cancer after D2 gastrectomy. The Lancet
CrossRef12
Yung-Jue Bang, Young-Woo Kim, Han-Kwang Yang, Hyun Cheol Chung, Young-Kyu Park, Kyung Hee Lee, Keun-Wook Lee, Yong Ho Kim, Sang-Ik Noh, Jae Yong Cho, Young Jae Mok, Yeul Hong Kim, Jiafu Ji, Ta-Sen Yeh, Peter Button, Florin Sirzén, Sung Hoon Noh. (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. The Lancet
CrossRef13
Hiroshi Imamura, Yukinori Kurokawa, Toshimasa Tsujinaka, Kentaro Inoue, Yutaka Kimura, Shohei Iijima, Toshio Shimokawa, Hiroshi Furukawa. (2012) Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial. The Lancet Infectious Diseases
CrossRef14
J. Türck, W. Schepp. (2012) Diagnostik und Therapie des Magenkarzinoms. Der Gastroenterologe 7:1, 49-61
CrossRef15
Joong Ho Lee, Kyung Min Kim, Jae-Ho Cheong, Sung Hoon Noh. (2012) Current Management and Future Strategies of Gastric Cancer. Yonsei Medical Journal 53:2, 248
CrossRef16
De-shen Wang, Chao Ren, Miao-zhen Qiu, Hui-yan Luo, Zhi-qiang Wang, Dong-sheng Zhang, Feng-hua Wang, Yu-hong Li, Rui-hua Xu. (2011) Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumor Biology
CrossRef17
Hidefumi Aoyama. 2011. Assessing Radiation Therapy. , 255-268.
CrossRef18
Scott A. Hundahl. (2011) The potential value of bursectomy in operations for trans-serosal gastric adenocarcinoma. Gastric Cancer
CrossRef19
Masaki Aizawa, Naoto Gotohda, Shinichiro Takahashi, Masaru Konishi, Taira Kinoshita. (2011) Predictive Value of Baseline Neutrophil/Lymphocyte Ratio for T4 Disease in Wall-Penetrating Gastric Cancer. World Journal of Surgery 35:12, 2717-2722
CrossRef20
Yung-Jue Bang. (2011) Capecitabine in gastric cancer. Expert Review of Anticancer Therapy 11:12, 1791-1806
CrossRef21
Twisha Chakravarty, Christopher H. Crane, Jaffer A. Ajani, Paul F. Mansfield, Tina M. Briere, A. Sam Beddar, Henry Mok, Valerie K. Reed, Sunil Krishnan, Marc E. Delclos, Prajnan Das. (2011) Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy as Preoperative Treatment for Localized Gastric Adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics
CrossRef22
Qing Zhang, Jeremy Tey, Lihua Peng, Zhe Yang, Fei Xiong, Ruiyao Jiang, Taifu Liu, Shen Fu, Jiade J. Lu. (2011) Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma. Radiotherapy and Oncology
CrossRef23
H.-J. Meyer, A.H. Hölscher, F. Lordick, H. Messmann, S. Mönig, C. Schumacher, M. Stahl, H. Wilke, M. Möhler. (2011) Aktuelle S3-Leitlinie zur Chirurgie des Magenkarzinoms. Der Chirurg
CrossRef24
Changhua Yu, Ren Yu, Weiguo Zhu, Yaqi Song, Tao Li. (2011) Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. Journal of Cancer Research and Clinical Oncology
CrossRef25
Guillaume Piessen, David Amielh, Mathieu Messager, Edouard Vinatier, Emmanuelle Leteurtre, Jean Pierre Triboulet, Christophe Mariette. (2011) Is Pretreatment Endoscopic Biopsy a Good Predictor of Signet Ring Cell Histology in Gastric Carcinoma?. World Journal of Surgery
CrossRef26
Vikas Dudeja, Elizabeth B. Habermann, Anasooya Abraham, Wei Zhong, Helen M. Parsons, Jennifer F. Tseng, Waddah B. Al-Refaie. (2011) Is there a Role for Surgery with Adequate Nodal Evaluation Alone in Gastric Adenocarcinoma?. Journal of Gastrointestinal Surgery
CrossRef27
Bo Hultman, Jonas Lundkvist, Bengt Glimelius, Peter Nygren, Haile Mahteme. (2011) Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer. Acta Oncologica1-10
CrossRef28
Mathieu Messager, Jérémie H. Lefevre, Virginie Pichot-Delahaye, Amine Souadka, Guillaume Piessen, Christophe Mariette, Jean Pierre Arnaud, Jean Michel Balon, Frank Bonnetain, Frédéric Borie, Dorothée Brachet, Cécile Brigand, Nicolas Carrere, Xavier Benoit DʼJourno, Pierre Dechelotte, Jean Robert Delpero, Abdenaceur Dhari, Sylvain Fabre, Manuel Fernandez, Renaud Flamein, Brigitte Gillet, Aude Glaise, Olivier Glehen, Diane Goéré, Marie Guilbert, Jérôme Guiramand, Mohamed Hebbar, Noël Huten, Kevin Kraft, Emmanuelle Leteurtre, Damien Louis, Jean Yves Mabrut, Benjamin Mathieu, Bernard Meunier, Sophie Michalak, Francis Michot, Bertrand Millat, François Paye, Frédérique Peschaud, Denis Pezet, Marc Pocard, Ariane Poisson, Michel Prudhomme, Jean Marc Regimbeau, Timothée Thiébot, Pascal-Alexandre Thomas, Basile Tsilividis, Florence Vandois. (2011) The Impact of Perioperative Chemotherapy on Survival in Patients With Gastric Signet Ring Cell Adenocarcinoma. Annals of Surgery 254:5, 684-693
CrossRef29
Laurent Quero, Zineb Bouchbika, Honorine Kouto, Valerie Baruch-Hennequin, Jean-Marc Gornet, Nicolas Munoz, Isabelle Cojean-Zelek, Remi Houdart, Yves Panis, Patrice Valleur, Thomas Aparicio, Claude Maylin, Christophe Hennequin. (2011) Postoperative Chemotherapy Followed by Conformal Concomitant Chemoradiotherapy in High-Risk Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef30
Chaitan K. Narsule, Marissa M. Montgomery, Hiran C. Fernando. (2011) Evidence-Based Review of the Management of Cancers of the Gastroesophageal Junction. Thoracic Surgery Clinics
CrossRef31
L. E. Ferri, S. Ades, T. Alcindor, M. Chasen, V. Marcus, M. Hickeson, G. Artho, M. P. Thirlwell. (2011) Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Annals of Oncology
CrossRef32
Jaime Ruiz-Tovar, Francisco Javier Lacueva, Israel Oliver, Amparo Martínez, Rafael Calpena. (2011) Complicación de la radioquimioterapia postoperatoria en una paciente con cáncer gástrico. Cirugía Española 89:8, 554-555
CrossRef33
Johan L. Dikken, Marcel Verheij, Annemieke Cats, Edwin P. M. Jansen, Henk H. Hartgrink, Cornelis J. H. Velde. (2011) Extended lymph node dissection for gastric cancer from a European perspective. Gastric Cancer 14:4, 396-398
CrossRef34
X. Zhang, Z. Yan, J. Zhang, L. Gong, W. Li, J. Cui, Y. Liu, Z. Gao, J. Li, L. Shen, Y. Lu. (2011) Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Annals of Oncology 22:10, 2257-2266
CrossRef35
Sameer H. Patel, David A. Kooby. (2011) Gastric Adenocarcinoma Surgery and Adjuvant Therapy. Surgical Clinics of North America 91:5, 1039-1077
CrossRef36
Vikram K. Jain, David Cunningham, Ian Chau. (2011) Preoperative and Postoperative Chemotherapy for Gastric Cancer. Surgical Oncology Clinics of North America
CrossRef37
Chunyan Du, Ye Zhou, Kai Huang, Guangfa Zhao, Hong Fu, Yingqiang Shi. (2011) Defining a High-Risk Subgroup of Pathological T2N0 Gastric Cancer by Prognostic Risk Stratification for Adjuvant Therapy. Journal of Gastrointestinal Surgery
CrossRef38
Tamara Z. Vern-Gross, Anand T. Shivnani, Ke Chen, Christopher M. Lee, Jonathan D. Tward, O. Kenneth MacDonald, Christopher H. Crane, Mark S. Talamonti, Louis L. Munoz, William Small. (2011) Survival Outcomes in Resected Extrahepatic Cholangiocarcinoma: Effect of Adjuvant Radiotherapy in a Surveillance, Epidemiology, and End Results Analysis. International Journal of Radiation Oncology*Biology*Physics 81:1, 189-198
CrossRef39
Richard Sullivan, Jeffrey Peppercorn, Karol Sikora, John Zalcberg, Neal J Meropol, Eitan Amir, David Khayat, Peter Boyle, Philippe Autier, Ian F Tannock, Tito Fojo, Jim Siderov, Steve Williamson, Silvia Camporesi, J Gordon McVie, Arnie D Purushotham, Peter Naredi, Alexander Eggermont, Murray F Brennan, Michael L Steinberg, Mark De Ridder, Susan A McCloskey, Dirk Verellen, Terence Roberts, Guy Storme, Rodney J Hicks, Peter J Ell, Bradford R Hirsch, David P Carbone, Kevin A Schulman, Paul Catchpole, David Taylor, Jan Geissler, Nancy G Brinker, David Meltzer, David Kerr, Matti Aapro. (2011) Delivering affordable cancer care in high-income countries. The Lancet Oncology 12:10, 933-980
CrossRef40
Byung Woog Kang, Jong Gwang Kim, Yee Soo Chae, Yoo Jin Lee, Soo Jung Lee, Joon Ho Moon, Sang Kyun Sohn, Min Kyu Jung, Seong Woo Jeon, Yun-Jin Jang, Jongduk Seo, Yong Hyun Lee, Ohkyung Kwon, Ho Young Chung, Wansik Yu. (2011) Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Investigational New Drugs
CrossRef41
Vikas Dudeja, Greer Gay, Elizabeth B. Habermann, Todd. M. Tuttle, Jennifer F. Tseng, Barry W. Feig, Waddah B. Al-Refaie. (2011) Do Hospital Attributes Predict Guideline-Recommended Gastric Cancer Care in the United States?. Annals of Surgical Oncology
CrossRef42
Brendon M. Stiles, Farooq Mirza, Anthony Coppolino, Jeffrey L. Port, Paul C. Lee, Subroto Paul, Nasser K. Altorki. (2011) Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease. The Annals of Thoracic Surgery 92:2, 491-498
CrossRef43
Sotiria Mastoraki, Aikaterini Mastoraki, Nikolaos Lefantzis, Panagiotis Safioleas, George Sakorafas, Michael Safioleas. (2011) Controversies and Challenging Therapeutic Modalities in Gastric Cancer. Indian Journal of Surgery 73:4, 251-255
CrossRef44
Javier Gallego, Andrés Cervantes, Carles Pericay, Dolores Isla. (2011) SEOM clinical guidelines for the treatment of oesophageal cancer. Clinical and Translational Oncology 13:8, 520-524
CrossRef45
Iain Beehuat Tan, Tatiana Ivanova, Kiat Hon Lim, Chee Wee Ong, Niantao Deng, Julian Lee, Sze Huey Tan, Jeanie Wu, Ming Hui Lee, Chia Huey Ooi, Sun Young Rha, Wai Keong Wong, Alex Boussioutas, Khay Guan Yeoh, Jimmy So, Wei Peng Yong, Akira Tsuburaya, Heike Grabsch, Han Chong Toh, Steven Rozen, Jae Ho Cheong, Sung Hoon Noh, Wei Kiat Wan, Jaffer A. Ajani, Ju–Seog Lee, Manuel Salto–Tellez, Patrick Tan. (2011) Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Gastroenterology 141:2, 476-485.e11
CrossRef46
V. Valenti, J.L. Hernandez-Lizoaín, M.C. Beorlegui, J.A. Diaz-Gozalez, F.M. Regueira, J.J. Rodriguez, A. Viudez, I. Sola, J.A. Cienfuegos. (2011) Morbidity, mortality, and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy. Journal of Surgical Oncology 104:2, 124-129
CrossRef47
Yasser Saleh, Hanan Ahmed Wahba, Hend Ahmed El-Hadaad, Mohamed Al-Hemaly, Tamer Fady Youssef. (2011) Adjuvant chemoradiotherapy versus surgery alone for gastric adenocarcinoma. The Chinese-German Journal of Clinical Oncology 10:8, 450-454
CrossRef48
Katja Ott, Florian Lordick, Susanne Blank, Markus Büchler. (2011) Gastric cancer: surgery in 2011. Langenbeck's Archives of Surgery 396:6, 743-758
CrossRef49
Mi Hee Lee, Dongil Choi, Min Jung Park, Min Woo Lee. (2011) Gastric cancer: Imaging and staging with MDCT based on the 7th AJCC guidelines. Abdominal Imaging
CrossRef50
Deirdre J. Cohen, Elliot Newman, Syma Iqbal, Richard Y. Chang, Milan Potmesil, Theresa Ryan, Bernadine Donahue, Anurag Chandra, Mengling Liu, Minerva Utate, Spiros Hiotis, Leon H. Pachter, Howard Hochster, Franco Muggia. (2011) Postoperative Intraperitoneal 5-Fluoro-2′-Deoxyuridine Added to Chemoradiation in Patients Curatively Resected (R0) for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Annals of Surgical Oncology
CrossRef51
Juan A. Díaz-González, Javier Rodríguez, José L. Hernández-Lizoain, Raquel Ciérvide, Miren Gaztañaga, Iñigo San Miguel, Leire Arbea, J. Javier Aristu, Ana Chopitea, Fernando Martínez-Regueira, Víctor Valentí, Jesús García-Foncillas, Rafael Martínez-Monge, Jesús J. Sola. (2011) Patterns of Response After Preoperative Treatment in Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 80:3, 698-704
CrossRef52
Jaclyn Yoong, Michael Michael, Trevor Leong. (2011) Targeted Therapies for Gastric Cancer. Drugs 71:11, 1367-1384
CrossRef53
Federico Bozzetti. (2011) Nutritional support in oncologic patients: Where we are and where we are going. Clinical Nutrition
CrossRef54
Yong-Bin Ding, Tian-Song Xia, Jin-Dao Wu, Guo-Yu Chen, Shui Wang, Jian-Guo Xia. (2011) Surgical outcomes for gastric cancer of a single institute in southeast China. The American Journal of Surgery
CrossRef55
R C Fields, V E Strong, M Gönen, K A Goodman, N P Rizk, D P Kelsen, D H Ilson, L H Tang, M F Brennan, D G Coit, M A Shah. (2011) Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. British Journal of Cancer 104:12, 1840-1847
CrossRef56
Claire L. Donohoe, John V. Reynolds. (2011) Challenges in the Treatment of Gastroesophageal Cancer: Reply. World Journal of Surgery 35:6, 1411-1411
CrossRef57
(2011) Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 14:2, 113-123
CrossRef58
F. Lordick, G. Schumacher, M. Becker-Schiebe. (2011) Gastric cancer – still many questions to be solved. memo - Magazine of European Medical Oncology 4:2, 71-74
CrossRef59
Xiao-Jun Yang, Chao-Qun Huang, Tao Suo, Lie-Jun Mei, Guo-Liang Yang, Fu-Lin Cheng, Yun-Feng Zhou, Bin Xiong, Yutaka Yonemura, Yan Li. (2011) Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial. Annals of Surgical Oncology 18:6, 1575-1581
CrossRef60
Shi Chen, Ying-Bo Chen, Zhi-Wei Zhou, Wei Li, Xiao-Wei Sun, Da-Zhi Xu, Yuan-Fang Li, Yuan-Xiang Guan, Xing-Yu Feng, You-Qing Zhan. (2011) No Survival Benefit From Postoperative Adjuvant Chemotherapy After D2 Radical Resection for the Patients With Stage II Gastric Cancer. American Journal of Clinical Oncology 34:3, 309-313
CrossRef61
Chi-Tung Cheng, Chun-Yi Tsai, Jun-Te Hsu, Rohan Vinayak, Keng-Hao Liu, Chun-Nan Yeh, Ta-Sen Yeh, Tsann-Long Hwang, Yi-Yin Jan. (2011) Aggressive Surgical Approach for Patients with T4 Gastric Carcinoma: Promise or Myth?. Annals of Surgical Oncology 18:6, 1606-1614
CrossRef62
James Welsh, Arya Amini, Anna Likhacheva, Jeremy Erasmus J., Daniel Gomez, Marta Davila, Reza J. Mehran, Ritsuko Komaki, Zhongxing Liao, Wayne L. Hofstetter, Jeffrey Lee H., Manoop S. Bhutani, Jaffer A. Ajani. (2011) Update: Modern Approaches to the Treatment of Localized Esophageal Cancer. Current Oncology Reports 13:3, 157-167
CrossRef63
Geoff CHONG, Niall C TEBBUTT. (2011) Perioperative therapy for resectable gastric cancer: What does the future hold?. Asia-Pacific Journal of Clinical Oncology 7:2, 93-95
CrossRef64
Yoshiyuki Fujiwara, Shuji Takiguchi, Kiyokazu Nakajima, Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Kaoru Okada, Masaki Mori, Yuichiro Doki. (2011) Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients with Peritoneal Dissemination. Annals of Surgical Oncology
CrossRef65
Gui-Chao Li, Zhen Zhang, Xue-Jun Ma, Wei-Lie Gu, Ya-Nong Wang, Jin Li. (2011) Are biomarkers correlated with recurrence patterns in patients with resectable gastric adenocarcinoma. Molecular Biology Reports
CrossRef66
Ugwuji N. Maduekwe, Sam S. Yoon. (2011) An Evidence-Based Review of the Surgical Treatment of Gastric Adenocarcinoma. Journal of Gastrointestinal Surgery 15:5, 730-741
CrossRef67
Kazuhito Mita, Hideto Ito, Masato Fukumoto, Ryo Murabayashi, Kazuya Koizumi, Takashi Hayashi, Hiroyuki Kikuchi, Tadashi Kagaya. (2011) Alternating Treatment with S-1 Plus Low-Dose Cisplatin and S-1 Alone for Advanced Gastric Cancer. Journal of Gastrointestinal Surgery 15:5, 791-796
CrossRef68
Baldassarre Stea, Lisa J. Hazard, Victor J. Gonzalez, Russell Hamilton. (2011) The role of radiation therapy in the control of locoregional and metastatic cancer. Journal of Surgical Oncology 103:6, 627-638
CrossRef69
Carl C. Schimanski, Friederike Schlaegel, Mareike Jordan, Markus Moehler, George Sgourakis, Daniel G. Drescher, Peter R. Galle, Hauke Lang, Ines Gockel. (2011) VEGF-D Correlates with Metastatic Disease in Gastric Cancer Patients Undergoing Surgery. World Journal of Surgery 35:5, 1010-1016
CrossRef70
Jeffrey M Craft, Dennis Hallahan. (2011) Towards novel radiosensitizing agents: the role of cytosolic PLA2α in combined modality cancer therapy. Future Medicinal Chemistry 3:7, 835-843
CrossRef71
Peter A.S. Johnstone. (2011) Foreword. Current Problems in Cancer 35:3, 96
CrossRef72
Joshua D. Lawson, Jason K. Sicklick, Paul T. Fanta. (2011) Gastric Cancer. Current Problems in Cancer 35:3, 97-127
CrossRef73
Pamela L. Kunz, Amirkaveh Mojtahed, George A. Fisher, James M. Ford, Daniel T. Chang, Raymond R. Balise, Charles D. Bangs, Athena M. Cherry, Reetesh K. Pai. (2011) HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population. Applied Immunohistochemistry and Molecular Morphology1
CrossRef74
Alicia Okines, David Cunningham, Ian Chau. (2011) Targeting the human EGFR family in esophagogastric cancer. Nature Reviews Clinical Oncology 8:8, 492-503
CrossRef75
D H Roukos. (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. The Pharmacogenomics Journal 11:2, 81-92
CrossRef76
Justin E. Bekelman, Anand Shah, Stephen M. Hahn. (2011) Implications of comparative effectiveness research for radiation oncology. Practical Radiation Oncology 1:2, 72-80
CrossRef77
Christos Katsios, George Baltogiannis, Dimitrios H Roukos. (2011) Progress, challenges and new genome-based concepts in the multidisciplinary treatment of gastric cancer. Expert Review of Anticancer Therapy 11:4, 503-506
CrossRef78
Sheila N. Garland, Guy Pelletier, Andrew Lawe, Bradly J. Biagioni, Jay Easaw, Michael Eliasziw, David Cella, Oliver F. Bathe. (2011) Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument. Cancer 117:6, 1302-1312
CrossRef79
Kilian S. May, Gary Y. Yang, Nikhil I. Khushalani. (2011) The Role of Radiation in the Perioperative Treatment of Esophagogastric Cancer. Current Treatment Options in Oncology 12:1, 61-71
CrossRef80
Chris Deans, Matthew S. W. Yeo, Mu Yar Soe, Asim Shabbir, T. K. Ti, Jimmy B. Y. So. (2011) Cancer of the Gastric Cardia is Rising in Incidence in an Asian Population and is Associated with Adverse Outcome. World Journal of Surgery 35:3, 617-624
CrossRef81
Autumn J McRee, Stacy Cowherd, Andrew Z Wang, Richard M Goldberg. (2011) Chemoradiation therapy in the management of gastrointestinal malignancies. Future Oncology 7:3, 409-426
CrossRef82
Weijing Sun, James M. Metz, Maryann Gallagher, Peter J. O’Dwyer, Bruce Giantonio, Richard Whittington, Daniel G. Haller. (2011) Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas. Cancer Chemotherapy and Pharmacology 67:3, 621-627
CrossRef83
Amy T. Y. Chang, Wai Tong Ng, Ada L. Y. Law, Ki Man Ku, Michael C. H. Lee, Anne W. M. Lee. (2011) Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. Gastric Cancer 14:1, 63-71
CrossRef84
Satoru Iwasa, Yasuhide Yamada, Takeo Fukagawa, Takako Eguchi Nakajima, Ken Kato, Tetsuya Hamaguchi, Shinji Morita, Makoto Saka, Hitoshi Katai, Yasuhiro Shimada. (2011) Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification. Gastric Cancer 14:1, 28-34
CrossRef85
Christophe Mariette, Guillaume Piessen, Nicolas Briez, Caroline Gronnier, Jean Pierre Triboulet. (2011) Oesophagogastric junction adenocarcinoma: which therapeutic approach?. The Lancet Oncology 12:3, 296-305
CrossRef86
María Sereno, Javier Castro, Paloma Cejas, Miguel Angel García-Cabezas, Cristóbal Belda, Enrique Casado, Jaime Feliu, César Gómez, Miriam López, Manuel González Barón. (2011) Expression Profile as Predictor of Relapse after Adjuvant Treatment in Gastric Cancer. Journal of Gastrointestinal Cancer
CrossRef87
M. Saka, S. Morita, T. Fukagawa, H. Katai. (2011) Present and Future Status of Gastric Cancer Surgery. Japanese Journal of Clinical Oncology 41:3, 307-313
CrossRef88
Branislav Bystricky, Alicia F.C. Okines, David Cunningham. (2011) Optimal Therapeutic Strategies for Resectable Oesophageal or Oesophagogastric Junction Cancer. Drugs 71:5, 541-555
CrossRef89
G. Spizzo, D. Öfner, A. Vries, P. Lukas, G. Steger, U. Pluschnig, J. Zacherl, J. Widder, A. Zabernigg, G. Gastl, G. Mühlmann. (2011) Preoperative Chemotherapy with Cisplatin and Docetaxel Followed by Surgery and Clip-Oriented Postoperative Chemoradiation in Patients with Localized Gastric or Gastroesophageal Junction Adenocarcinoma: Results from a Phase II Feasibility Study. Annals of Surgical Oncology 18:3, 677-683
CrossRef90
Deepa Reddy, Zev A. Wainberg. (2011) Targeted Therapies for Metastatic Esophagogastric Cancer. Current Treatment Options in Oncology 12:1, 46-60
CrossRef91
Benjamin Garlipp, Jens Schwalenberg, Daniela Adolf, Hans Lippert, Frank Meyer. (2011) Epidemiology, Surgical Management and Early Postoperative Outcome in a Cohort of Gastric Cancer Patients of a Tertiary Referral Center in Relation to Multi-Center Quality Assurance Studies. Polish Journal of Surgery 83:3, 123-134
CrossRef92
H. S. Ahn, H.-J. Lee, M.-W. Yoo, S.-H. Jeong, D.-J. Park, H.-H. Kim, W. H. Kim, K. U. Lee, H.-K. Yang. (2011) Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. British Journal of Surgery 98:2, 255-260
CrossRef93
J.-S. Kim, M.-A. Kim, D.-Y. Oh, S.-H. Lee, D.-W. Kim, S.-A. Im, W. H. Kim, H.-K. Yang, D. S. Heo, Y.-J. Bang, K.-U. Lee, T.-Y. Kim. (2011) Increasing Nodal Ratio is a Poor Prognostic Factor for Survival in Stage III-IV (M0) Gastric Cancer Patients Who Received Curative Surgery Followed by Adjuvant Chemotherapy: A Retrospective Study. Japanese Journal of Clinical Oncology 41:2, 245-252
CrossRef94
Theodore Liakakos, Christos Katsios, Dimitrios H Roukos. (2011) Gastroesophageal junction carcinoma multimodal treatment: standards, debate and new therapeutic options. Expert Review of Gastroenterology & Hepatology 5:1, 1-4
CrossRef95
Ross A. Abrams, Kathryn A. Winter, William F. Regine, Howard Safran, John P. Hoffman, Robert Lustig, Andre A. Konski, Al B. Benson, John S. Macdonald, Tyvin A. Rich. (2011) Failure to Adhere to Protocol Specified Radiation Therapy Guidelines was Associated with Decreased Survival in RTOG 9704—A Phase III Trial of Adjuvant Chemotherapy and Chemoradiotherapy for Patients with Resected Adenocarcinoma of the Pancreas. International Journal of Radiation OncologyBiologyPhysics
CrossRef96
M. F. Raphael, I. Kluijt, B. G. Koot, A. M. J. B. Smets, M. E. C. Tilanus, J. Bras, M. D. van de Wetering. (2011) Gastric Adenocarcinoma in a 13-Year-Old Boy: a Diagnosis not Often Seen in This Age Group. Pediatric Hematology-Oncology 28:1, 71-77
CrossRef97
Warner Alpízar-Alpízar, Ib Jarle Christensen, Eric Santoni-Rugiu, Arne Skarstein, Kjell Ovrebo, Martin Illemann, Ole Didrik Laerum. (2011) Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma. International Journal of Cancern/a-n/a
CrossRef98
Li-Hua Shao, Shao-Ping Liu, Jin-Xuan Hou, Yan-Hua Zhang, Chun-Wei Peng, Yan-Jun Zhong, Xiong Liu, Xiu-Li Liu, Ya-Ping Hong, Raymond A. Firestone, Yan Li. (2011) Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis. Cancern/a-n/a
CrossRef99
Vikas Dudeja, Elizabeth B. Habermann, Wei Zhong, Todd M. Tuttle, Selwyn M. Vickers, Eric H. Jensen, Waddah B. Al-Refaie. (2011) Guideline Recommended Gastric Cancer Care in the Elderly: Insights into the Applicability of Cancer Trials to Real World. Annals of Surgical Oncology 18:1, 26-33
CrossRef100
Hirofumi Asakura, Takayuki Hashimoto, Hideyuki Harada, Masashi Mizumoto, Kazuhisa Furutani, Noriaki Hasuike, Masaki Matsuoka, Hiroyuki Ono, Narikazu Boku, Tetsuo Nishimura. (2011) Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate?. Journal of Cancer Research and Clinical Oncology 137:1, 125-130
CrossRef101
Shigeyuki Tamura, Atsushi Takeno, Hirofumi Miki. (2011) Lymph Node Dissection in Curative Gastrectomy for Advanced Gastric Cancer. International Journal of Surgical Oncology 2011, 1-8
CrossRef102
Hiromitsu Domen, Masanori Ohara, Misa Noguchi, Yoshitsugu Nakanishi, Kazuteru Komuro, Nozomu Iwashiro, Masanori Ishizaka. (2011) Long-Term Survival of Resected Advanced Gastric Cancer with Hepatic and Pancreatic Invasion. Case Reports in Gastroenterology 5:2, 396-403
CrossRef103
F.J.F. Coimbra, W.L. Costa, A.L. Montagnini, A.L. Diniz, H.S.C. Ribeiro, M.J.B. Silva, M.F.S. Begnami. (2011) The interaction between N-category and N-ratio as a new tool to improve lymph node metastasis staging in gastric cancer: Results of a single cancer center in Brazil. European Journal of Surgical Oncology (EJSO) 37:1, 47-54
CrossRef104
Johan L Dikken, Johanna W van Sandick, HA Maurits Swellengrebel, Pehr A Lind, Hein Putter, Edwin PM Jansen, Henk Boot, Nicole CT van Grieken, Cornelis JH van de Velde, Marcel Verheij, Annemieke Cats. (2011) Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 11:1, 329
CrossRef105
Luis F. Oñate-Ocaña, Natalia Velázquez-Monroy, Luis Vázquez, Pablo Espinosa-Mireles-de-Villafranca, Elvia Núñez-Rosas, Maira Ovando-Lezama, Diana Vilar-Compte, Gabriela García-Hubard, José F. Carrillo, Jane M. Blazeby, Vincenzo Aiello-Crocifoglio. (2011) Clinical validation of the EORTC QLQ-OG25 questionnaire for the evaluation of health-related quality of life in Mexican patients with esophagogastric cancers. Psycho-Oncologyn/a-n/a
CrossRef106
Xiaolong Zhang, Nanjing Li, Wen Wei, Wenxiu Yao, Ke Xie, Jiankun Hu, Lida Shen, Weizheng Ji, You Lu, Feng Wen, Yu Jiang, Feng Xu, Hong Feng, Feng Bi, Qiu Li, . (2011) Clinical management of gastric cancer: results of a multicentre survey. BMC Cancer 11:1, 369
CrossRef107
Thomas Rösch, Shajan Peter, Shyam Varadarajulu. 2011. EUS in the Evaluation of Gastric Tumors. , 97-114.
CrossRef108
Okan ORHAN, Celalettin EROGLU, Bünyamin KAPLAN, Kadir UCAR, Mustafa ALTINBAS, Metin OZKAN, Dilek UNAL, Oguz Galip YILDIZ, Serdar SOYUER. (2011) Whole Abdominal Field versus Standard Field Radiotherapy plus Concomitant and Adjuvant Chemotherapy for Patients with Locally Advanced Gastric Cancer. Journal of Radiation Research 52:2, 168-175
CrossRef109
Sung Joon Kwon. (2011) Evaluation of the 7th UICC TNM Staging System of Gastric Cancer. Journal of Gastric Cancer 11:2, 78
CrossRef110
Wei-hua Zhou, Fang Tang, Jie Xu, Xing Wu, Zhi-ying Feng, Hai-gang Li, Dong-jun Lin, Chun-kui Shao, Quentin Liu. (2011) Aberrant upregulation of 14-3-3ơ expression serves as an inferior prognostic biomarker for gastric cancer. BMC Cancer 11:1, 397
CrossRef111
Yoshinaga Okugawa, Yuji Toiyama, Koji Tanaka, Kohei Matsusita, Hiroyuki Fujikawa, Susumu Saigusa, Masaki Ohi, Yasuhiro Inoue, Yasuhiko Mohri, Keiichi Uchida, Masato Kusunoki. (2011) Clinical significance of zinc finger E-box binding homeobox 1 (ZEB1) in human gastric cancer. Journal of Surgical Oncologyn/a-n/a
CrossRef112
Yulia Kundel, Ofer Purim, Efraim Idelevich, Konstantin Lavrenkov, Sofia Man, Svetlana Kovel, Natalia Karminsky, Raphael M Pfeffer, Bella Nisenbaum, Eyal Fenig, Aaron Sulkes, Baruch Brenner. (2011) Postoperative Chemoradiation for Resected Gastric Cancer - Is the MacDonald Regimen Tolerable? A Retrospective Multi-Institutional Study. Radiation Oncology 6:1, 127
CrossRef113
Bo-Gun Jang, Woo Ho Kim. (2011) Molecular Pathology of Gastric Carcinoma. Pathobiology 78:6, 302-310
CrossRef114
Kazuhiro Yoshida, Kazuya Yamaguchi, Naoki Okumura, Shinji Osada, Takao Takahashi, Yoshihiro Tanaka, Kazuaki Tanabe, Takahisa Suzuki. (2011) The Roles of Surgical Oncologists in the New Era – Minimally Invasive Surgery for Early Gastric Cancer and Adjuvant Surgery for Metastatic Gastric Cancer. Pathobiology 78:6, 343-352
CrossRef115
Yoshiyuki Fujiwara, Shuji Takiguchi, Kiyokazu Nakajima, Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Masaki Mori, Yuichiro Doki. (2011) Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. Journal of Surgical Oncologyn/a-n/a
CrossRef116
Karen E. Hoffman, Bridget A. Neville, Harvey J. Mamon, Lisa A. Kachnic, Matthew S. Katz, Craig C. Earle, Rinaa S. Punglia. (2011) Adjuvant therapy for elderly patients with resected gastric adenocarcinoma. Cancern/a-n/a
CrossRef117
Seok Yun Kang, Jae Ho Han, Mi Sun Ahn, Hyun Woo Lee, Seong Hyun Jeong, Joon Seong Park, Yong Kwan Cho, Sang-Uk Han, Young Bae Kim, Jang Hee Kim, Seung Soo Sheen, Ho-Yeong Lim, Jin-Hyuk Choi. (2011) Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection. International Journal of Cancern/a-n/a
CrossRef118
Zi-Yu Li, Cherry E. Koh, Zhao-De Bu, Ai-Wen Wu, Lian-Hai Zhang, Xiao-Jiang Wu, Qi Wu, Xiang-Long Zong, Hui Ren, Lei Tang, Xiao-Peng Zhang, Ji-You Li, Ying Hu, Lin Shen, Jia-Fu Ji. (2011) Neoadjuvant chemotherapy with FOLFOX: Improved outcomes in Chinese patients with locally advanced gastric cancer. Journal of Surgical Oncologyn/a-n/a
CrossRef119
Amedeo Amedei, Marisa Benagiano, Chiara della Bella, Elena Niccolai, Mario M. D'Elios. (2011) Novel Immunotherapeutic Strategies of Gastric Cancer Treatment. Journal of Biomedicine and Biotechnology 2011, 1-17
CrossRef120
Ravi Shridhar, George W. Dombi, Steven E. Finkelstein, Kenneth L. Meredith, Sarah E. Hoffe. (2011) Improved survival in patients with lymph node-positive gastric cancer who received preoperative radiation. Cancern/a-n/a
CrossRef121
Sup Kim, Jun-Sang Kim, Hyun-Yong Jeong, Seung-Moo Noh, Ki-Whan Kim, Moon-June Cho. (2011) Retrospective analysis of treatment outcomes after postoperative chemoradiotherapy in advanced gastric cancer. Radiation Oncology Journal 29:4, 252
CrossRef122
Chunyan Du, Ye Zhou, Hong Cai, Guangfa Zhao, Hong Fu, Ying-Qiang Shi. (2011) Poor prognostic factors in patients with stage I gastric cancer according to the seventh edition TNM classification: A comparative analysis of three subgroups. Journal of Surgical Oncologyn/a-n/a
CrossRef123
Ayelet Dreznik, Ofer Purim, Efraim Idelevich, Yulia Kundel, Jaqueline Sulkes, Aaron Sulkes, Baruch Brenner. (2011) Gastric cancer: Biology and clinical manifestations in Israel. Journal of Surgical Oncologyn/a-n/a
CrossRef124
C Matuschek, E Bölke, M Peiper, WT Knoefel, W Budach, A Erhardt, A Scherer, PA Gerber, BA Buhren, N Gattermann, SE Baldus, E Rusnak, V Shukla, K Orth. (2011) The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. European Journal of Medical Research 16:6, 265
CrossRef125
Gitonga Munene, Wesley Francis, Sheila N. Garland, Guy Pelletier, Lloyd A. Mack, Oliver F. Bathe. (2011) The quality of life trajectory of resected gastric cancer. Journal of Surgical Oncologyn/a-n/a
CrossRef126
Hironori Ohdaira, Yutaka Suzuki, Mai Tsutsui, Taizo Iwasaki, Munefumi Arita, Takuji Noro, Naruo Kawasaki, Tadashi Ohara, Keiichi Yoshino, Hajime Kuroda, Masaki Kitajima. (2010) Laparoscopy-assisted Total Gastrectomy for Advanced Gastric Cancer With Carcinomatous Ascites After S1 Plus Cisplatin Chemotherapy. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 20:6, e206-e210
CrossRef127
Hyuk-Chan KWON, Min Chan KIM, Ki Han KIM, Jin Seok JANG, Sung Yong OH, Sung-Hyun KIM, Kyung A. KWON, Suee LEE, Hyung Sik LEE, Hyo-Jin KIM. (2010) Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia-Pacific Journal of Clinical Oncology 6:4, 278-285
CrossRef128
Magdolna Dank. (2010) A gyomorrák kezelésének aktualitásai. I. rész. Gyógyszeres terápia. Magyar Onkológia 54:4, 337-341
CrossRef129
Xin Wang, Yongsheng Wang, Meng Qiu, Qiu Li, Zhi-ping Li, Bing He, Feng Xu, Ya-li Shen, Hong-feng Gou, Yu Yang, Dan Cao, Cheng Yi, Ji-yan Liu, De-yun Luo, Zheng-yin Liao, Feng Bi. (2010) Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen). Medical Oncology
CrossRef130
Matthew J. Schuchert, James D. Luketich, Rodney J. Landreneau. (2010) Management of Esophageal Cancer. Current Problems in Surgery 47:11, 845-946
CrossRef131
Yixing Jiang, Jaffer A Ajani. (2010) Multidisciplinary management of gastric cancer. Current Opinion in Gastroenterology 26:6, 640-646
CrossRef132
Abeer A. Saad, Nahla M. Awed, Nashwa N. A. Abd Elkerim, Dina EL-Shennawy, Marian A. Alfons, Mohamed E. Elserafy, Yaser W. Darwish, Eman M. F. Barakat, Sahar S. Ezz-Elarab. (2010) Prognostic Significance of E-cadherin Expression and Peripheral Blood Micrometastasis in Gastric Carcinoma Patients. Annals of Surgical Oncology 17:11, 3059-3067
CrossRef133
Eelco de Bree, Vasilis Charalampakis, John Melissas, Dimitris D. Tsiftsis. (2010) The extent of lymph node dissection for gastric cancer: A critical appraisal. Journal of Surgical Oncology 102:6, 552-562
CrossRef134
A. F. C. Okines, D. Cunningham. (2010) Multimodality treatment for localized gastro-oesophageal cancer. Annals of Oncology 21:Supplement 7, vii286-vii293
CrossRef135
Aviram Nissan, Alfredo Garofalo, Jesus Esquivel. (2010) Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for gastric adenocarcinoma: Why haven't we reached the promised land?. Journal of Surgical Oncology 102:5, 359-360
CrossRef136
Julien Jézéquel, Christophe Bessaguet, Cedric Verveur, Joseph Faycal, Zoe Richert, Jean-Philippe Metges, Alain Volant, Jean-Baptiste Nousbaum, Michel Robaszkiewicz. (2010) Trends in incidence, management, and survival of gastric and cardia carcinomas in the area of Finistere (France) between 1984 and 2003. European Journal of Gastroenterology & Hepatology1
CrossRef137
Tsuyoshi Etoh, Masafumi Inomata, Norio Shiraishi, Seigo Kitano. (2010) Revisional Surgery After Gastrectomy for Gastric Cancer. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 20:5, 332-337
CrossRef138
Javier Lacueva, Javier Gallego, Juan Antonio Díaz-González. (2010) Updating controversies on the multidisciplinary management of gastric cancer. Clinical and Translational Oncology 12:10, 677-685
CrossRef139
Ahmed Salem, Sameh Hashem, Layth Y. I. Mula-Hussain, Issa Mohammed, Ala’a Nour, Wael Shelpai, Faiez Daoud, Basem Morcos, Yasser Yamin, Imad Jaradat, Jamal Khader, Abdelatief Almousa. (2010) Management Strategies for Locoregional Recurrence in Early-Stage Gastric Cancer: Retrospective Analysis and Comprehensive Literature Review. Journal of Gastrointestinal Cancer
CrossRef140
Takanori Maruyama, Koji Kono, Yoshiki Mizukami, Yoshihiko Kawaguchi, Kousaku Mimura, Mitsuaki Watanabe, Shinichirou Izawa, Hideki Fujii. (2010) Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Science 101:9, 1947-1954
CrossRef141
A. Baraniskin, A. Tannapfel, A. Reinacher-Schick. (2010) Neoadjuvante Therapie von Tumoren des oberen Gastrointestinaltrakts. Der Gastroenterologe 5:5, 412-422
CrossRef142
M. Sasako, M. Inoue, J.-T. Lin, C. Khor, H.-K. Yang, A. Ohtsu. (2010) Gastric Cancer Working Group Report. Japanese Journal of Clinical Oncology 40:Supplement 1, i28-i37
CrossRef143
A. Lang, U. Graeven. (2010) Adjuvante Therapie gastrointestinaler Tumoren. Der Gastroenterologe 5:5, 423-429
CrossRef144
Jun Nakamura, Yoshihiko Kitajima, Keita Kai, Kazuyoshi Hashiguchi, Masatsugu Hiraki, Hirokazu Noshiro, Kohji Miyazaki. (2010) HIF-1α is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy. International Journal of Cancer 127:5, 1158-1171
CrossRef145
Maarten Lambrecht, Karin Haustermans. (2010) Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiotherapy and Oncology 96:3, 339-346
CrossRef146
Michael I. Koukourakis, Alexandra Giatromanolaki, Michael Pitiakoudis, George Kouklakis, Pelagia Tsoutsou, Ioannis Abatzoglou, Marianthi Panteliadou, Kyriaki Sismanidou, Efthimios Sivridis, Teni Boulikas. (2010) Concurrent Liposomal Cisplatin (Lipoplatin), 5-Fluorouracil and Radiotherapy for the Treatment of Locally Advanced Gastric Cancer: A Phase I/II Study. International Journal of Radiation Oncology*Biology*Physics 78:1, 150-155
CrossRef147
Sung Sook Lee, Hei-Cheul Jeung, Hyun Cheol Chung, Sung Hoon Noh, Woo Jin Hyung, Ji Yeong Ahn, Sun Young Rha. (2010) A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. Investigational New Drugs
CrossRef148
Nicholas W. Choong, Ann M. Mauer, Daniel C. Haraf, Mark K. Ferguson, Alan B. Sandler, Kenneth A. Kesler, Paul A. S. Fishkin, Rafat H. Ansari, James Wade, Stuart A. Krauss, David F. Sciortino, Mitchell C. Posner, Masha Kocherginsky, Philip C. Hoffman, Livia Szeto, Everett E. Vokes. (2010) Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Medical Oncology
CrossRef149
A. Yuriko Minn, Annie Hsu, Trang La, Pamela Kunz, George A. Fisher, James M. Ford, Jeffrey A. Norton, Brendan Visser, Karyn A. Goodman, Albert C. Koong, Daniel T. Chang. (2010) Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer 116:16, 3943-3952
CrossRef150
Yutaka Tanizawa, Masanori Terashima. (2010) Lymph node dissection in the resection of gastric cancer: Review of existing evidence. Gastric Cancer 13:3, 137-148
CrossRef151
R. J. Cohen, K. Paskalev, S. Litwin, R. A. Price Jr., S. J. Feigenberg, A. A. Konski. (2010) Original article: Esophageal motion during radiotherapy: quantification and margin implications. Diseases of the Esophagus 23:6, 473-479
CrossRef152
Takeo Fukagawa, Mitsuru Sasako, Seiji Ito, Hayao Nakanishi, Hisae Iinuma, Shoji Natsugoe, Hitoshi Katai, Tadakazu Shimoda. (2010) The prognostic significance of isolated tumor cells in the lymph nodes of gastric cancer patients. Gastric Cancer 13:3, 191-196
CrossRef153
, Yasuhiro Kodera, Akiharu Ishiyama, Takaki Yoshikawa, Takashi Kinoshita, Seiji Ito, Hiroyuki Yokoyama, Yoshinari Mochizuki, Hiroaki Ito, Akira Tsuburaya, Junichi Sakamoto, Akimasa Nakao. (2010) A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer 13:3, 197-203
CrossRef154
Dennis Chung-Kei Ng, Simon Kin-Hung Wong, Wai-Tong Ng, Anne Wing-Mui Lee, Michael Ka-Wah Li. (2010) Impact of adjuvant chemoradiation for adenocarcinoma of stomach after curative gastrectomy in Chinese: A 7-year audit. Surgical Practice 14:3, 85-91
CrossRef155
D.G. Power, J.V. Reynolds. (2010) Localized adenocarcinoma of the esophagogastric junction – Is there a standard of care?. Cancer Treatment Reviews 36:5, 400-409
CrossRef156
Masanori Tokunaga, Shigekazu Ohyama, Naoki Hiki, Tetsu Fukunaga, Susumu Aikou, Toshiharu Yamaguchi. (2010) Can Superextended Lymph Node Dissection be Justified for Gastric Cancer with Pathologically Positive Para-aortic Lymph Nodes?. Annals of Surgical Oncology 17:8, 2031-2036
CrossRef157
Yan Yi, Jinming Yu, Baosheng Li, Fujun Yang, Wei Huang, Hongfu Sun, Heyi Gong, Tao Zhou, Haiqun Lin. (2010) Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume delineation of regional lymph node in patients with gastric carcinoma. Radiotherapy and Oncology 96:2, 223-230
CrossRef158
M.W. Saif, N. Makrilia, A. Zalonis, M. Merikas, K. Syrigos. (2010) Gastric cancer in the elderly: An overview. European Journal of Surgical Oncology (EJSO) 36:8, 709-717
CrossRef159
Ahmet Bilici, Mesut Seker, Bala Basak Oven Ustaalioglu, Umut Kefeli, Emre Yildirim, Dilek Yavuzer, Fatih Muhammed Aydin, Taflan Salepci, Mustafa Oncel, Mahmut Gumus. (2010) Prognostic Significance of Perineural Invasion in Patients with Gastric Cancer Who Underwent Curative Resection. Annals of Surgical Oncology 17:8, 2037-2044
CrossRef160
You-Jin Jang, Jong-Han Kim, Sung-Soo Park, Seong-Heum Park, Seung-Joo Kim, Chong-Suk Kim, Young-Jae Mok. (2010) Metastatic Lymph Node Targeted Chemosensitivity Test for Gastric Cancer. Journal of Surgical Research
CrossRef161
Natalie G. Coburn, Laercio G. Lourenco, Seana E. Rossi, Nadia Gunraj, Alyson L. Mahar, Lucy K. Helyer, Calvin Law, Linda Rabeneck, Lawrence Paszat. (2010) Management of gastric cancer in Ontario. Journal of Surgical Oncology 102:1, 54-63
CrossRef162
Edwin P.M. Jansen, Jasper Nijkamp, Michael Gubanski, Pehr A.R.M. Lind, Marcel Verheij. (2010) Interobserver Variation of Clinical Target Volume Delineation in Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 77:4, 1166-1170
CrossRef163
Hye–Jong Song, Amitabh Srivastava, Jeeyun Lee, Yun Soo Kim, Kyoung–Mee Kim, Won Ki Kang, Minji Kim, Seonwoo Kim, Cheol Keun Park, Sung Kim. (2010) Host Inflammatory Response Predicts Survival of Patients With Epstein-Barr Virus–Associated Gastric Carcinoma. Gastroenterology 139:1, 84-92.e2
CrossRef164
Hesham Hossiny, Nashaat Diab, Maha Taher. (2010) A comparative dosimetric study of adjuvant 3D conformal radiotherapy for operable stomach cancer versus AP-PA conventional radiotherapy in NCI-Cairo. The Chinese-German Journal of Clinical Oncology 9:7, 401-405
CrossRef165
Alicia F.C. Okines, David Cunningham. (2010) Trastuzumab in gastric cancer. European Journal of Cancer 46:11, 1949-1959
CrossRef166
S. Dixit, M. Tilston, W. M. Peter. (2010) Risk stratification for recurrence in patients with esophageal and junctional carcinoma treated with neoadjuvant chemotherapy and surgery. Medical Oncology 27:2, 242-248
CrossRef167
Francesco Recchia, Giampiero Candeloro, Gabriele Guerriero, Juan Piazze, Giovambattista Desideri, Stefano Necozione, Silvio Rea. (2010) Liposomal pegylated doxorubicin and oxaliplatin as salvage chemotherapy in patients with metastatic gastric cancer treated earlier. Anti-Cancer Drugs 21:5, 559-564
CrossRef168
Lakshmi Rajdev. (2010) Treatment Options for Surgically Resectable Gastric Cancer. Current Treatment Options in Oncology 11:1-2, 14-23
CrossRef169
Max Dahele, Matthew Skinner, Brenda Schultz, Marlene Cardoso, Chris Bell, Yee C. Ung. (2010) Adjuvant Radiotherapy for Gastric Cancer: A Dosimetric Comparison of 3-Dimensional Conformal Radiotherapy, Tomotherapy® and Conventional Intensity Modulated Radiotherapy Treatment Plans. Medical Dosimetry 35:2, 115-121
CrossRef170
Jing Sun, Yi-Hong Sun, Zhao-Chong Zeng, Xin-Yu Qin, Meng-Su Zeng, Bing Chen, Tian-Shu Liu, Jian-Ying Zhang. (2010) Consideration of the Role of Radiotherapy for Abdominal Lymph Node Metastases in Patients With Recurrent Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 77:2, 384-391
CrossRef171
Shinichi Hasegawa, Takaki Yoshikawa. (2010) Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer 13:2, 63-73
CrossRef172
Jingyu Deng, Han Liang, Dan Sun, Yi Pan. (2010) The Prognostic Analysis of Lymph Node-Positive Gastric Cancer Patients Following Curative Resection. Journal of Surgical Research 161:1, 47-53
CrossRef173
Gilbert Mühlmann, Gerold Untergasser, Matthias Zitt, Marion Zitt, Hans Maier, Gregor Mikuz, Irmgard E. Kronberger, Michael C. Haffner, Eberhard Gunsilius, Dietmar Öfner. (2010) Immunohistochemically detectable dickkopf-3 expression in tumor vessels predicts survival in gastric cancer. Virchows Archiv 456:6, 635-646
CrossRef174
Thorvardur R. Halfdanarson, Robert R. McWilliams, John H. Donohue, J. Fernando Quevedo. (2010) A single-institution experience with 491 cases of small bowel adenocarcinoma. The American Journal of Surgery 199:6, 797-803
CrossRef175
Benjamin W. Corn, Ravit Geva. (2010) Determining the role of radiotherapy in the adjuvant management of gastric cancer: an ocean apart. Cancer Chemotherapy and Pharmacology 65:6, 1005-1007
CrossRef176
Ilfet Songun, Hein Putter, Elma Meershoek-Klein Kranenbarg, Mitsuru Sasako, Cornelis JH van de Velde. (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. The Lancet Oncology 11:5, 439-449
CrossRef177
Aristotelis Bamias, M. Karina, P. Papakostas, I. Kostopoulos, M. Bobos, G. Vourli, E. Samantas, Ch. Christodoulou, G. Pentheroudakis, D. Pectasides, M. A. Dimopoulos, G. Fountzilas. (2010) A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemotherapy and Pharmacology 65:6, 1009-1021
CrossRef178
A. Okines, M. Verheij, W. Allum, D. Cunningham, A. Cervantes, . (2010) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v50-v54
CrossRef179
Ugwuji N. Maduekwe, Gregory Y. Lauwers, Carlos Fernandez-del-Castillo, David L. Berger, Charles M. Ferguson, David W. Rattner, Sam S. Yoon. (2010) New Metastatic Lymph Node Ratio System Reduces Stage Migration in Patients Undergoing D1 Lymphadenectomy for Gastric Adenocarcinoma. Annals of Surgical Oncology 17:5, 1267-1277
CrossRef180
Kevin K Roggin, Josh Hemmerich, Mitchell C Posner. (2010) Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait?. The Lancet Oncology 11:5, 404-405
CrossRef181
Barbara Wysocka, Zahra Kassam, Gina Lockwood, James Brierley, Laura A. Dawson, Carol Ann Buckley, David Jaffray, Bernard Cummings, John Kim, Rebecca Wong, Jolie Ringash. (2010) Interfraction and Respiratory Organ Motion During Conformal Radiotherapy in Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 77:1, 53-59
CrossRef182
F. Roviello, C. Pedrazzani, D. Marrelli, A. Di Leo, S. Caruso, S. Giacopuzzi, G. Corso, G. de Manzoni. (2010) Super-extended (D3) lymphadenectomy in advanced gastric cancer. European Journal of Surgical Oncology (EJSO) 36:5, 439-446
CrossRef183
Mario Scartozzi, Mirco Pistelli, Alessandro Bittoni, Riccardo Giampieri, Eva Galizia, Rossana Berardi, Luca Faloppi, Michela Prete, Stefano Cascinu. (2010) Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy. Current Oncology Reports 12:3, 175-185
CrossRef184
Geoffrey Y. Ku, David H. Ilson. (2010) Esophagogastric cancer: Targeted agents. Cancer Treatment Reviews 36:3, 235-248
CrossRef185
Masashi Fujii, Mitsugu Kochi, Tadatoshi Takayama. (2010) Recent advances in chemotherapy for advanced gastric cancer in Japan. Surgery Today 40:4, 295-300
CrossRef186
Charles C. Hsu, Joseph M. Herman, Michele M. Corsini, Jordan M. Winter, Matthew D. Callister, Michael G. Haddock, John L. Cameron, Timothy M. Pawlik, Richard D. Schulick, Christopher L. Wolfgang, Daniel A. Laheru, Michael B. Farnell, Michael J. Swartz, Leonard L. Gunderson, Robert C. Miller. (2010) Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study. Annals of Surgical Oncology 17:4, 981-990
CrossRef187
Joshua Strauss, Dawn L. Hershman, Donna Buono, Russell McBride, Sean Clark-Garvey, Shermian A. Woodhouse, Julian A. Abrams, Alfred I. Neugut. (2010) Use of Adjuvant 5-Fluorouracil and Radiation Therapy After Gastric Cancer Resection Among the Elderly and Impact on Survival. International Journal of Radiation Oncology*Biology*Physics 76:5, 1404-1412
CrossRef188
A.E. Dassen, V.E.P.P. Lemmens, L.V. van de Poll-Franse, G.J. Creemers, S.J. Brenninkmeijer, D.J. Lips, A.A.M. vd Wurff, K. Bosscha, J.W.W. Coebergh. (2010) Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: A population-based study in the Netherlands. European Journal of Cancer 46:6, 1101-1110
CrossRef189
Anna Dorothea Wagner, Susanne Unverzagt, Wilfried Grothe, Gerhard Kleber, Axel Grothey, Johannes Haerting, Wolfgang E. Fleig, Anna Dorothea Wagner. 2010. Chemotherapy for advanced gastric cancer. .
CrossRef190
Rafael Diaz-Nieto, Massimo Varcada, Marc Winslet, Rafael Diaz-Nieto. 2010. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. .
CrossRef191
James J. Mezhir, Laura H. Tang, Daniel G. Coit. (2010) Neoadjuvant therapy of locally advanced gastric cancer. Journal of Surgical Oncology 101:4, 305-314
CrossRef192
Carlos Robles-Jara, Carlos Robles-Medranda. (2010) Endoscopic Chemotherapy with 5-Fluorouracil in Advanced Gastric Cancer. Journal of Gastrointestinal Cancer 41:1, 75-78
CrossRef193
Takeshi Yokoe, Yuji Toiyama, Yoshinaga Okugawa, Koji Tanaka, Masaki Ohi, Yasuhiro Inoue, Yasuhiko Mohri, Chikao Miki, Masato Kusunoki. (2010) KAP1 Is Associated With Peritoneal Carcinomatosis in Gastric Cancer. Annals of Surgical Oncology 17:3, 821-828
CrossRef194
Zhe Sun, Hui-mian Xu. (2010) Stage and Microscopic Positive Margins in the Treatment of Patients with Gastric Cancer. Annals of Surgical Oncology 17:3, 943-945
CrossRef195
Chun-Nan Yeh, Shih-Ming Jung, Tsung-Wen Chen, Tsann-Long Hwang, Yi-Yin Jan, Miin-Fu Chen. (2010) Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy. Langenbeck's Archives of Surgery 395:3, 217-225
CrossRef196
Brian D. Kavanagh, Charlie C. Pan, Laura A. Dawson, Shiva K. Das, X. Allen Li, Randall K. Ten Haken, Moyed Miften. (2010) Radiation Dose–Volume Effects in the Stomach and Small Bowel. International Journal of Radiation Oncology*Biology*Physics 76:3, S101-S107
CrossRef197
E. P. M. Jansen, H. Boot, R. Dubbelman, M. Verheij, A. Cats. (2010) Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy. Annals of Oncology 21:3, 530-534
CrossRef198
Cristina P. Rodriguez, David J. Adelstein, Thomas W. Rice, Lisa A. Rybicki, Gregory M. M. Videtic, Jerrold P. Saxton, Sudish C. Murthy, David P. Mason, Denise I. Ives. (2010) A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer. Journal of Thoracic Oncology 5:2, 229-235
CrossRef199
Melanie Goldfarb, Steven Brower, S. D. Schwaitzberg. (2010) Minimally invasive surgery and cancer: controversies part 1. Surgical Endoscopy 24:2, 304-334
CrossRef200
K. Avery, R. Hughes, A. McNair, D. Alderson, P. Barham, J. Blazeby. (2010) Health-related quality of life and survival in the 2years after surgery for gastric cancer. European Journal of Surgical Oncology (EJSO) 36:2, 148-154
CrossRef201
Marcel Verheij, Conchita Vens, Baukelien van Triest. (2010) Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective. Drug Resistance Updates 13:1-2, 29-43
CrossRef202
David Schreiber, Justin Rineer, Dan Vongtama, Angela Wortham, Peter Han, David Schwartz, Kwang Choi, Marvin Rotman. (2010) Impact of Postoperative Radiation after Esophagectomy for Esophageal Cancer. Journal of Thoracic Oncology 5:2, 244-250
CrossRef203
Waddah B. Al-Refaie, Greer Gay, Beth A. Virnig, Jennifer F. Tseng, Andrew Stewart, Selwyn M. Vickers, Todd. M. Tuttle, Barry W. Feig. (2010) Variations in gastric cancer care. Cancer 116:2, 465-475
CrossRef204
Corrado Pedrazzani, Armands Sivins, Guntis Ancans, Daniele Marrelli, Giovanni Corso, Viesturs Krumins, Franco Roviello, Marcis Leja. (2010) Ratio Between Metastatic and Examined Lymph Nodes (N Ratio) May Have Low Clinical Utility in Gastric Cancer Patients Treated by Limited Lymphadenectomy: Results from a Single-Center Experience of 526 Patients. World Journal of Surgery 34:1, 85-91
CrossRef205
Naveenraj L. Solomon, Michael C. Cheung, Margaret M. Byrne, Ying Zhuge, Dido Franceschi, Alan S. Livingstone, Leonidas G. Koniaris. (2010) Does Chemoradiotherapy Improve Outcomes for Surgically Resected Adenocarcinoma of the Stomach or Esophagus?. Annals of Surgical Oncology 17:1, 98-108
CrossRef206
Stephen A. Barnett, Nabil P. Rizk. (2010) Randomized Clinical Trials in Esophageal Carcinoma. Surgical Oncology Clinics of North America 19:1, 59-80
CrossRef207
G. Lurje, H. Husain, D. G. Power, D. Yang, S. Groshen, A. Pohl, W. Zhang, Y. Ning, P. C. Manegold, A. El-Khoueiry, S. Iqbal, L. H. Tang, M. A. Shah, H.-J. Lenz. (2010) Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Annals of Oncology 21:1, 78-86
CrossRef208
KK Murthy, KA Shukeili, SS Kumar, CA Davis, RR Chandran, S Namrata. (2010) Evaluation of dose coverage to target volume and normal tissue sparing in the adjuvant radiotherapy of gastric cancers: 3D-CRT compared with dynamic IMRT. Biomedical Imaging and Intervention Journal 6:3,
CrossRef209
Ji Hoon Choi, Min Kyu Kang, Myung Se Kim, Sung Kyu Kim, Sang Mo Yun, Sung Hoon Kim. (2010) The Results of Intraoperative Radiotherapy for Stomach Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology 28:2, 79
CrossRef210
Seulkee Park, Yanghee Woo, Hogeun Kim, Yong Chan Lee, Sungho Choi, Woo Jin Hyung, Sung Hoon Noh. (2010) In Vitro Adenosine Triphosphate Based Chemotherapy Response Assay in Gastric Cancer. Journal of Gastric Cancer 10:4, 155
CrossRef211
Bryan A. Whitson, Shawn S. Groth, Zhongze Li, Robert A. Kratzke, Michael A. Maddaus. (2010) Survival of patients with distal esophageal and gastric cardia tumors: A population-based analysis of gastroesophageal junction carcinomas. The Journal of Thoracic and Cardiovascular Surgery 139:1, 43-48
CrossRef212
Masanori Tokunaga, Naoki Hiki. (2010) Reply to “Lymphadenectomy in Gastric Cancer: The Controversy Refuses to Die”. Annals of Surgical Oncology 17:1, 336-337
CrossRef213
J. Kim, C.-L. Sun, B. Mailey, C. Prendergast, A. Artinyan, S. Bhatia, A. Pigazzi, J. D. I. Ellenhorn. (2010) Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Annals of Oncology 21:1, 152-160
CrossRef214
James J. Mezhir, Venu G. Pillarisetty, Manish A. Shah, Daniel G. Coit. (2010) Randomized Clinical Trials in Gastric Cancer. Surgical Oncology Clinics of North America 19:1, 81-100
CrossRef215
Yuji Uchikawa, Takenari Nakata, Shiro Miwa, Akira Kobayashi, Takeshi Uehara, Shinichi Miyagawa. (2010) Signet-Ring Cell Carcinoma of the Ampulla of Vater: A Case Report. The Japanese Journal of Gastroenterological Surgery 43:4, 391-397
CrossRef216
John C. Deutsch. 2010. Gastric Cancer. , 68-72.
CrossRef217
Irena Oblak, Franc Anderluh, Vaneja Velenik. (2009) Postoperative radiochemotherapy for gastric adenocarcinoma: long term results. Radiology and Oncology 43:4, 274-281
CrossRef218
Ilfet Songun, Cornelis JH van de Velde. (2009) Optimal surgery for advanced gastric cancer. Expert Review of Anticancer Therapy 9:12, 1849-1858
CrossRef219
Masanori Tokunaga, Naoki Hiki, Tetsu Fukunaga, Shigekazu Ohyama, Toshiharu Yamaguchi, Toshifusa Nakajima. (2009) Better 5-Year Survival Rate Following Curative Gastrectomy in Overweight Patients. Annals of Surgical Oncology 16:12, 3245-3251
CrossRef220
Manas Kumar Roy, Sagar Sadhu, Sanjay Kumar Dubey. (2009) Advances in the management of gastric cancer. Indian Journal of Surgery 71:6, 342-349
CrossRef221
Fernando Rivera, Maica Galán, Josep Tabernero, Andres Cervantes, M. Eugenia Vega-Villegas, Javier Gallego, Berta Laquente, Edith Rodríguez, Alfredo Carrato, Pilar Escudero, Bartomeu Massutí, Vicente Alonso-Orduña, Adelaida Cardenal, Alberto Sáenz, Jordi Giralt, Ana Lucia Yuste, Antonio Antón, Enrique Aranda. (2009) Phase II Trial of Preoperative Irinotecan–Cisplatin Followed by Concurrent Irinotecan–Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics 75:5, 1430-1436
CrossRef222
Víctor Valentí, José Luis Hernández-Lizoain, Fernando Martínez Regueira, Aurora Gil, Pablo Martí, Gabriel Zozaya, Álvaro Bueno, Nicolás Pedano, Jorge Arredondo, M. Carmen Beorlegui, Javier Álvarez-Cienfuegos. (2009) Análisis de la morbilidad postoperatoria en pacientes con adenocarcinoma gástrico tratados según protocolo de quimiorradioterapia preoperatoria y cirugía. Cirugía Española 86:6, 351-357
CrossRef223
Guillaume Piessen, Mathieu Messager, Emmanuelle Leteurtre, Triboulet Jean-Pierre, Christophe Mariette. (2009) Signet Ring Cell Histology is an Independent Predictor of Poor Prognosis in Gastric Adenocarcinoma Regardless of Tumoral Clinical Presentation. Annals of Surgery 250:6, 878-887
CrossRef224
Orhan Onder Eren, Mehmet Artac, Melih Cem Boruban, Ozlem Yavas, Ugur Arslan, Metin Basaranoglu. (2009) Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience. Medical Oncology 26:4, 386-392
CrossRef225
R. Semrau, D. Vallböhmer, A.H. Hölscher, R.-P. Müller. (2009) Neoadjuvante Therapie der Adenokarzinome des oberen Gastrointestinaltraktes. Der Chirurg 80:11, 1035-1041
CrossRef226
Tetsuji Fujita. (2009) Gastric cancer. The Lancet 374:9701, 1593-1594
CrossRef227
K. Ott, F. Lordick. (2009) Neoadjuvante Therapie im oberen Gastrointestinaltrakt. Der Chirurg 80:11, 1028-1034
CrossRef228
Y. Kodera, S. Ito, Y. Mochizuki, K. Kondo, K. Koshikawa, N. Suzuki, H. Kojima, T. Kojima, T. Matsui, T. Takase, K. Tsuboi, M. Fujiwara, A. Nakao. (2009) A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). European Journal of Surgical Oncology (EJSO) 35:11, 1158-1163
CrossRef229
Takaki Yoshikawa, Akira Tsuburaya, Naoki Hirabayashi, Kazuhiro Yoshida, Naoki Nagata, Yasuhiro Kodera, Naoto Takahashi, Koji Oba, Masayuki Kimura, Satoshi Ishikura, Yumi Miyashita, Junichi Sakamoto. (2009) A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma. Cancer Chemotherapy and Pharmacology 64:6, 1071-1077
CrossRef230
Anya N. Milne, F. Carneiro, C. O’Morain, G. J. A. Offerhaus. (2009) Nature meets nurture: molecular genetics of gastric cancer. Human Genetics 126:5, 615-628
CrossRef231
H. Wilke, M. Stahl. (2009) Therapie beim Magenkarzinom. Der Chirurg 80:11, 1023-1027
CrossRef232
Benjamin W. Corn, Dan Schifter, Shlomo Alani, Natan Strauss, Viacheslav Soyfer. (2009) In Reply to Dr. Lohr et al.. International Journal of Radiation Oncology*Biology*Physics 75:2, 635-636
CrossRef233
David J. Adelstein, Thomas W. Rice, Lisa A. Rybicki, Jerrold P. Saxton, Gregory M. M. Videtic, Sudish C. Murthy, David P. Mason, Cristina P. Rodriguez, Denise I. Ives. (2009) Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction. Journal of Thoracic Oncology 4:10, 1264-1269
CrossRef234
Kentaro Inoue, Yasushi Nakane, Taku Michiura, Sou Yamaki, Rintaro Yui, Kazuhito Sakuramoto, Aiko Iwai, Katsuji Tokuhara, Yoshiro Araki, Songtae Kim, Koji Nakai, Mutsuya Sato, Keigo Yamamichi, A-Hon Kwon. (2009) Feasibility and accuracy of second-look laparoscopy after gastrectomy for gastric cancer. Surgical Endoscopy 23:10, 2307-2313
CrossRef235
Stacey A. DaCosta Byfield, Craig C. Earle, John Z. Ayanian, Ellen P. McCarthy. (2009) Treatment and outcomes of gastric cancer among United States-born and foreign-born Asians and Pacific Islanders. Cancer 115:19, 4595-4605
CrossRef236
(2009) Case 19-2009: Carcinoma of the Gastroesophageal Junction. New England Journal of Medicine 361:13, 1315-1316
Full Text237
Yutaka Yonemura, Yoshio Endou, Masaya Shinbo, Takuma Sasaki, Masamitu Hirano, Akiyoshi Mizumoto, Takayuki Matsuda, Nobuyuki Takao, Masumi Ichinose, Mitsukuni Mizuno, Masahiro Miura, Makoto Ikeda, Satoshi Ikeda, Gou Nakajima, Jou Yonemura, Takafumi Yuuba, Seiji Masuda, Hironobu Kimura, Nobuo Matsuki. (2009) Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. Journal of Surgical Oncology 100:4, 311-316
CrossRef238
Aviram Nissan, Alexander Stojadinovic, Alfredo Garofalo, Jesus Esquivel, Pompiliu Piso. (2009) Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future. Journal of Surgical Oncology 100:4, 335-344
CrossRef239
Ying Zhuge, Michael C. Cheung, Relin Yang, Dalal Eldick, Leonidas G. Koniaris, Juan E. Sola. (2009) Pediatric Intestinal Foregut and Small Bowel Solid Tumors: A Review of 105 Cases. Journal of Surgical Research 156:1, 95-102
CrossRef240
Robert Wesolowski, Chan Lee, Richard Kim. (2009) Is there a role for second-line chemotherapy in advanced gastric cancer?. The Lancet Oncology 10:9, 903-912
CrossRef241
Douglas G. Gold, Robert C. Miller, Michael G. Haddock, Leonard L. Gunderson, Fernando Quevedo, John H. Donohue, Sumita Bhatia, David M. Nagorney. (2009) Adjuvant Therapy for Gallbladder Carcinoma: The Mayo Clinic Experience. International Journal of Radiation Oncology*Biology*Physics 75:1, 150-155
CrossRef242
C.G. Willett, B.G. Czito. (2009) Chemoradiotherapy in Gastrointestinal Malignancies. Clinical Oncology 21:7, 543-556
CrossRef243
Bernhard Berger, Claus Belka. (2009) Evidence-based radiation oncology: Oesophagus. Radiotherapy and Oncology 92:2, 276-290
CrossRef244
Fernando Rivera, Alfredo Carrato, Cristina Grávalos, Carles Pericay, Javier Sastre, Enrique Aranda. (2009) Recommendations on current approach to gastric cancer. Clinical and Translational Oncology 11:8, 518-525
CrossRef245
JEEYUN LEE, WON KI KANG, JOON OH PARK, SE HOON PARK, YOUNG SUK PARK, HO YEONG LIM, JUNGA KIM, JEEHYUN KONG, MIN GEW CHOI, TAE SUNG SOHN, JAE HYUNG NOH, JAE MOON BAE, SUNG KIM, DO HOON LIM, KYOUNG-MEE KIM, CHEOL KEUN PARK. (2009) Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS 117:8, 598-606
CrossRef246
Anna Dorothea Wagner, Ulrich Wedding. (2009) Advances in the Pharmacological Treatment of Gastro-Oesophageal Cancer. Drugs & Aging 26:8, 627-646
CrossRef247
Vincenzo Valentini, Francesco Cellini, Bruce D. Minsky, Gian Carlo Mattiucci, Mario Balducci, Giuseppe D’Agostino, Elisa D’Angelo, Nicola Dinapoli, Nicola Nicolotti, Chiara Valentini, Giuseppe La Torre. (2009) Survival after radiotherapy in gastric cancer: Systematic review and meta-analysis. Radiotherapy and Oncology 92:2, 176-183
CrossRef248
Vincenzo Catalano, Roberto Labianca, Giordano D. Beretta, Gemma Gatta, Filippo de Braud, Eric Van Cutsem. (2009) Gastric cancer. Critical Reviews in Oncology/Hematology 71:2, 127-164
CrossRef249
Henk H Hartgrink, Edwin PM Jansen, Nicole CT van Grieken, Cornelis JH van de Velde. (2009) Gastric cancer. The Lancet 374:9688, 477-490
CrossRef250
Mario Scartozzi, Alessandro Bittoni, Mirco Pistelli, Eva Galizia, Rossana Berardi, Riccardo Giampieri, Luca Faloppi, Stefano Cascinu. (2009) Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives. Cancer Treatment Reviews 35:5, 451-462
CrossRef251
Wenzhen Yuan, Bin Ma, Yumin Li, Quanlin Guan, Yuyuan Zhao, Lijuan Yang, Donghai Wang, Yumin Li. 2009. Radiotherapy for gastric cancer. .
CrossRef252
Geoffrey Y. Ku, David H. Ilson. (2009) Role of Neoadjuvant Therapy for Esophageal Adenocarcinoma. Surgical Oncology Clinics of North America 18:3, 533-546
CrossRef253
Young-Jin Kim, Han-Ik Bae, Oh Kyoung Kwon, Myung-Seok Choi. (2009) Three-dimensional gastric cancer cell culture using nanofiber scaffold for chemosensitivity test. International Journal of Biological Macromolecules 45:1, 65-71
CrossRef254
Alexandra Leary, L. Assersohn, D. Cunningham, A. R. Norman, G. Chong, G. Brown, P. J. Ross, C. Costello, L. Higgins, J. Oates. (2009) A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology 64:3, 455-462
CrossRef255
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Kwak, Eunice L., Hong, Theodore S., Berger, David L., Forcione, David G., Uppot, Raul N., Lauwers, Gregory Y., . (2009) Case 19-2009. New England Journal of Medicine 360:25, 2656-2664
Full Text256
Alessandro Morabito, Guido Carillio, Raffaele Longo. (2009) Systemic treatment of gastric cancer. Critical Reviews in Oncology/Hematology 70:3, 216-234
CrossRef257
Jingyu Deng, Han Liang. (2009) D2 lymphadenectomy in gastric cancer surgery. Clinical Oncology and Cancer Research 6:3, 162-168
CrossRef258
Junichi Sakamoto, Takanori Matsui, Yasuhiro Kodera. (2009) Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer 12:2, 69-78
CrossRef259
Shlomo Alani, Viacheslav Soyfer, Natan Strauss, Dan Schifter, Benjamin W. Corn. (2009) Limited Advantages of Intensity-Modulated Radiotherapy Over 3D Conformal Radiation Therapy in the Adjuvant Management of Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 74:2, 562-566
CrossRef260
Mitsuru Sasako, Yukinori Kurokawa. (2009) Challenges in performing surgical randomized controlled trials in Japan. Surgery 145:6, 598-602
CrossRef261
A. Muratore, G. Zimmitti, R. Lo Tesoriere, A. Mellano, P. Massucco, L. Capussotti. (2009) Low rates of loco-regional recurrence following extended lymph node dissection for gastric cancer. European Journal of Surgical Oncology (EJSO) 35:6, 588-592
CrossRef262
Jun Ho Lee, Young-Suk Cho, Ji Young Lee, Myoung Cheorl Kook, Jong-Whan Park, Byung-Ho Nam, Jae-Moon Bae. (2009) The Chemokine Receptor CCR4 is Expressed and Associated With a Poor Prognosis in Patients With Gastric Cancer. Annals of Surgery 249:6, 933-941
CrossRef263
P.M. Schneider, M.K. Müller, M. Schiesser. (2009) Chirurgische Therapiestrategien beim Ösophagus- und Magenkarzinom. Der Gastroenterologe 4:3, 209-223
CrossRef264
T. Liakakos, G. Karatzas. (2009) Predicting Prognosis of Gastric Cancer: Limitations of Metastatic Lymph Nodes Number and Promise of Genomics. Annals of Surgical Oncology 16:5, 1432-1433
CrossRef265
F. Lordick, K. Ott. (2009) Neoadjuvante und adjuvante Therapie des Magen- und Ösophaguskarzinoms. Der Gastroenterologe 4:3, 224-231
CrossRef266
Masahiko Nishiyama, Hidetaka Eguchi. (2009) Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy. Advanced Drug Delivery Reviews 61:5, 402-407
CrossRef267
Marcia Bockbrader, Edward Kim. (2009) Role of intensity-modulated radiation therapy in gastrointestinal cancer. Expert Review of Anticancer Therapy 9:5, 637-647
CrossRef268
C. Jackson, D. Cunningham, J. Oliveira, . (2009) Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv34-iv36
CrossRef269
Perry Shen, John H. Stewart, Edward A. Levine. (2009) Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Non-Colorectal Indications. Current Problems in Cancer 33:3, 168-193
CrossRef270
Hei-Cheul Jeung, Sun Young Rha, Sang Joon Shin, Joong Bae Ahn, Jae Kyung Roh, Chan Hee Park, Sung Hoon Noh, Hyun Cheol Chung. (2009) Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. Cancer Chemotherapy and Pharmacology 63:5, 919-927
CrossRef271
William Allum, Alfredo Garofalo, Maurizio Degiuli, Christoph Schuhmacher. (2009) The first European Union Network of Excellence for Gastric Cancer conference, Rome, Italy, April 2008. Gastric Cancer 12:1, 56-65
CrossRef272
H. H. Hartgrink. (2009) Improving outcome for scirrhous gastric cancer. Gastric Cancer 12:1, 3-5
CrossRef273
Dimitrios H. Roukos. (2009) Genome-Wide Association Studies and Aggressive Surgery Toward Individualized Prevention, and Improved Local Control and Overall Survival for Gastric Cancer. Annals of Surgical Oncology 16:4, 795-798
CrossRef274
Koji Oba. (2009) Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. International Journal of Clinical Oncology 14:2, 85-89
CrossRef275
Natalie G. Coburn. (2009) Lymph nodes and gastric cancer. Journal of Surgical Oncology 99:4, 199-206
CrossRef276
Geoffrey Y. Ku, David H. Ilson. (2009) Preoperative Therapy for Esophageal Cancer. Gastroenterology Clinics of North America 38:1, 135-152
CrossRef277
Christine Binquet, Michal Abrahamowicz, Karine Astruc, Jean Faivre, Claire Bonithon-Kopp, Catherine Quantin. (2009) Flexible statistical models provided new insights into the role of quantitative prognostic factors for mortality in gastric cancer. Journal of Clinical Epidemiology 62:3, 232-240
CrossRef278
Maria Sereno, Javier castro, Cristóbal Belda-Iniesta, Miguel Angel Garcia-Cabezas, Paloma Cejas, Enrique Casado, Jorge Barriuso, Jaime Feliu, Javier Larrauri. (2009) EPO-R Expression Patterns in Resected Gastric Adenocarcinoma Followed by Adjuvant Chemoradiation Treatment. Pathology & Oncology Research 15:1, 1-10
CrossRef279
T. Fukagawa, M. Sasako, T. Shimoda, T. Sano, H. Katai, M. Saka, G. B. Mann, M. Karpeh, D. G. Coit, M. F. Brennan. (2009) The Prognostic Impact of Isolated Tumor Cells in Lymph Nodes of T2N0 Gastric Cancer: Comparison of American and Japanese Gastric Cancer Patients. Annals of Surgical Oncology 16:3, 609-613
CrossRef280
A. R. Skandarajah, A. C. Lynch, J. R. Mackay, S. Ngan, A. G. Heriot. (2009) The Role of Intraoperative Radiotherapy in Solid Tumors. Annals of Surgical Oncology 16:3, 735-744
CrossRef281
Luisa Adán Merino, Silvia Gomez Senent, Eduardo Alonso Gamarra. (2009) Estrategia diagnóstica y terapéutica en el adenocarcinoma gástrico. Medicina Clínica 132:6, 230-236
CrossRef282
Da-zhi Xu, Qi-rong Geng, Zi-jie Long, You-qing Zhan, Wei Li, Zhi-wei Zhou, Ying-bo Chen, Xiao-wei Sun, Gong Chen, Quentin Liu. (2009) Positive Lymph Node Ratio Is an Independent Prognostic Factor in Gastric Cancer After D2 Resection Regardless of the Examined Number of Lymph Nodes. Annals of Surgical Oncology 16:2, 319-326
CrossRef283
Roderick M. Quiros, Courtney L. Bui. (2009) Multidisciplinary Approach to Esophageal and Gastric Cancer. Surgical Clinics of North America 89:1, 79-96
CrossRef284
Karin Oechsle, Carsten Bokemeyer, Jörg T. Hartmann, Wilfried Budach, Tanja Trarbach, Michael Stahl, Ina Boehlke, Christian Kollmannsberger. (2009) Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group. Journal of Cancer Research and Clinical Oncology 135:2, 163-172
CrossRef285
Ilfet Songun, Cornelis JH van de Velde. (2009) How does extended lymphadenectomy influence practical care for patients with gastric cancer?. Nature Clinical Practice Oncology 6:2, 66-67
CrossRef286
Domenico D'Ugo, Stefano Rausei, Alberto Biondi, Roberto Persiani. (2009) Preoperative treatment and surgery in gastric cancer: friends or foes?. The Lancet Oncology 10:2, 191-195
CrossRef287
Ross A. Abrams. (2009) Cholangiocarcinoma—What Level of Evidence Should We Have?. International Journal of Radiation Oncology*Biology*Physics 73:1, 1-2
CrossRef288
Mark J. Krasna. (2009) Stage-Specific Therapy for Cancer of the Oesophagus. Drugs & Aging 26:3, 185-194
CrossRef289
Mitsuru Sasako. (2009) Adjuvant chemotherapy with 5-FU or regimens including oral fluoropyrimidine for curable gastric cancer. Gastric Cancer 12:S1, 10-15
CrossRef290
Jeong Nam Cho, Yong Ho Kim. (2009) Clinicopathologic Evaluation of Patients with Recurrence of Gastric Cancer within 6 Months after Curative Resection. Journal of the Korean Surgical Society 77:6, 385
CrossRef291
Hong Qiu, Masakazu Yashiro, Osamu Shinto, Taro Matsuzaki, Kosei Hirakawa. (2009) DNA methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of gastric cancer cells. Cancer Science 100:1, 181-188
CrossRef292
E. Fatourou, A. Macheras, E. P. Misiakos, T. Liakakos. (2009) Perioperative Chemotherapy for Gastric Cancer. Annals of Surgical Oncology 16:1, 226-227
CrossRef293
Ralf-Dieter Hofheinz, Frederik Wenz, Nadine Lukan, Sabine Mai, Melanie Kripp, Wilko Staiger, Matthias Schwarzbach, Frank Willeke, Markus Möhler, Stefan Post, Andreas Hochhaus. (2009) Oxaliplatin and Capecitabine-Based Chemoradiotherapy for Gastric Cancer—An Extended Phase I MARGIT and AIO Trial. International Journal of Radiation Oncology*Biology*Physics 73:1, 142-147
CrossRef294
Tae Kyung Ha, Min Sung Jung, Kang Hong Lee, Kyeong Geun Lee, Sung Joon Kwon. (2009) The Effect of Adjuvant Chemotherapy on Stage IV (T4N1-3M0 and T1-3N3M0) Gastric Cancer. Cancer Research and Treatment 41:1, 19
CrossRef295
Dong Hyun Kim, Won Taek Kim, Mi Ran Lee, Yong Gan Ki, Ji Ho Nam, Dal Park, Ho Sang Jeon, Kye Rok Jeon, Dong Won Kim. (2009) Influence of Delayed Gastric Emptying in Radiotherapy after a Subtotal Gastrectomy. The Journal of the Korean Society for Therapeutic Radiology and Oncology 27:4, 194
CrossRef296
Hoon Hur, Cho Hyun Park. (2009) Surgical Treatment of Gastric Carcinoma. The Korean Journal of Gastroenterology 54:2, 83
CrossRef297
Markus Menges, Thomas Hoehler. (2009) Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. Journal of Cancer Research and Clinical Oncology 135:1, 29-38
CrossRef298
Philip Abraham Kovoor, Jimmy Hwang. (2009) Treatment of resectable gastric cancer: current standards of care. Expert Review of Anticancer Therapy 9:1, 135-142
CrossRef299
P. Sun, J.-B. Xiang, Z.-Y. Chen. (2009) Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. British Journal of Surgery 96:1, 26-33
CrossRef300
Víctor Valentí, José Luis Hernández-Lizoain, Fernando Martínez Regueira, Aurora Gil, Pablo Martí, Gabriel Zozaya, Álvaro Bueno, Nicolás Pedano, Jorge Arredondo, M. Carmen Beorlegui, Javier Álvarez-Cienfuegos. (2009) Analysis of postoperative morbidity in patients with gastric adenocarcinoma treated using a protocol of preoperative chemoradiotherapy and surgery. Cirugía Española (English Edition) 86:6, 351-357
CrossRef301
Wei Liu, Xiaodong Zhang, Weijing Sun. (2008) Developments in Treatment of Esophageal/Gastric Cancer. Current Treatment Options in Oncology 9:4-6, 375-387
CrossRef302
Geoffrey Y Ku, David H Ilson. (2008) Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. Expert Review of Anticancer Therapy 8:12, 1953-1964
CrossRef303
Yukinori Kurokawa, Mitsuru Sasako. (2008) Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers: adjuvant chemoradiotherapy for gastric cancer. International Journal of Clinical Oncology 13:6, 479-482
CrossRef304
E. Wöll. (2008) Gastric cancer. memo - Magazine of European Medical Oncology 1:4, 263-265
CrossRef305
Yasuhiro Kodera. (2008) Disseminated cancer cells in the peritoneal cavity: what can we do when we detect them?. Gastric Cancer 11:4, 192-193
CrossRef306
Shen Fu, Jiade J. Lu, Qing Zhang, Zhe Yang, Lihua Peng, Fei Xiong. (2008) Intraoperative Radiotherapy Combined With Adjuvant Chemoradiotherapy for Locally Advanced Gastric Adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics 72:5, 1488-1494
CrossRef307
(2008) Nodal Dissection for Gastric Cancer. New England Journal of Medicine 359:22, 2392-2393
Full Text308
Javier Escrig Sos, David Martínez Ramos. (2008) New technologies in cancer and their assessment. The clinical surgeon’s point of view. Clinical and Translational Oncology 10:11, 713-718
CrossRef309
S. Scaringi, R. Kianmanesh, J.M. Sabate, E. Facchiano, P. Jouet, B. Coffin, G. Parmentier, J.M. Hay, Y. Flamant, S. Msika. (2008) Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: A single western center experience. European Journal of Surgical Oncology (EJSO) 34:11, 1246-1252
CrossRef310
Ylanga G. van der Geld, Baukelien van Triest, Wilko F.A.R. Verbakel, John R. van Sörnsen de Koste, Suresh Senan, Ben J. Slotman, Frank J. Lagerwaard. (2008) Evaluation of Four-Dimensional Computed Tomography-Based Intensity-Modulated and Respiratory-Gated Radiotherapy Techniques for Pancreatic Carcinoma. International Journal of Radiation Oncology*Biology*Physics 72:4, 1215-1220
CrossRef311
A. Gondos, F. Bray, T. Hakulinen, H. Brenner, . (2008) Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Annals of Oncology 20:3, 564-573
CrossRef312
E. Bollschweiler, R. Metzger, U. Drebber, S. Baldus, D. Vallbohmer, M. Kocher, A. H. Holscher. (2008) Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Annals of Oncology 20:2, 231-238
CrossRef313
Luis F. Oñate-Ocaña, Mauricio Becker, José F. Carrillo, Vincenzo Aiello-Crocifoglio, Dolores Gallardo-Rincón, Rocío Brom-Valladares, Roberto Herrera-Goepfert, Francisco Ochoa-Carrillo, Arturo Beltrán-Ortega. (2008) Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. Journal of Surgical Oncology 98:5, 336-342
CrossRef314
T. Liakakos, E. Fatourou, D. Ziogas, E. Lykoudis, Dimitrios H. Roukos. (2008) Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancer—Promises and Reality. Annals of Surgical Oncology 15:10, 2981-2982
CrossRef315
Kevin R. Kozak, John S. Moody. (2008) The Survival Impact of the Intergroup 0116 Trial on Patients With Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 72:2, 517-521
CrossRef316
Charles A. Coltman. (2008) The Southwest Oncology Group: Progress in Cancer Research. Seminars in Oncology 35:5, 545-552
CrossRef317
Pierre Senesse, Eric Assenat, Stéphane Schneider, Cyrus Chargari, Nicolas Magné, David Azria, Xavier Hébuterne. (2008) Nutritional support during oncologic treatment of patients with gastrointestinal cancer: Who could benefit?. Cancer Treatment Reviews 34:6, 568-575
CrossRef318
Andrew P. Barbour, Mark Jones, Mithat Gonen, David C. Gotley, Janine Thomas, Damien B. Thomson, Bryan Burmeister, B. Mark Smithers. (2008) Refining Esophageal Cancer Staging After Neoadjuvant Therapy: Importance of Treatment Response. Annals of Surgical Oncology 15:10, 2894-2902
CrossRef319
Robert A. Wolff, Gauri R. Varadhachary, Douglas B. Evans. (2008) Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress. Annals of Surgical Oncology 15:10, 2773-2786
CrossRef320
P.J. Shukla, R.S.K. Pavoor, G.S. Barreto. (2008) Gastric cancer in Europe ( Br J Surg 2008; 95: 406-408). British Journal of Surgery 95:9, 1189-1189
CrossRef321
T. Liakakos, E. Fatourou. (2008) Stage-Specific Guided Adjuvant Treatment for Gastric Cancer. Annals of Surgical Oncology 15:9, 2622-2623
CrossRef322
Florian Lordick, Theo Ruers, Daniela E. Aust, Laurence Collette, Robert J Downey, Mostafa El Hajjam, Patrick Flamen, Karen Haustermans, David Ilson, Catherine Julié, Bernd Joachim Krause, Hartwig Newiger, Katja Ott, Arnaud Roth, Eric Van Cutsem, Wolfgang A. Weber, Manfred P. Lutz. (2008) European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. European Journal of Cancer 44:13, 1807-1819
CrossRef323
Florian Lordick, Katja Ott, Jürgen Weitz, Dirk Jäger. (2008) The evolving role of catumaxomab in gastric cancer. Expert Opinion on Biological Therapy 8:9, 1407-1415
CrossRef324
T. Crosby. (2008) Scottish Intercollegiate Guidelines Network (SIGN) 87 — the Management of Oesophageal and Gastric Cancer. Clinical Oncology 20:7, 528-529
CrossRef325
D. Ziogas, T. Liakakos. (2008) Lessons from Laparoscopic Gastrectomy: Preventing Surgical Complications. Annals of Surgical Oncology 15:9, 2624-2625
CrossRef326
Michael G. House, Murray F. Brennan. (2008) Neoadjuvant Therapy for Gastric Cancer. Advances in Surgery 42, 151-168
CrossRef327
Dimosthenis Ziogas, George Baltogiannis, Michael Fatouros. (2008) Continuing Debate on D2 Lymphadenectomy for Gastric Cancer. World Journal of Surgery 32:9, 2127-2128
CrossRef328
Juan J. Grau, Miguel Caballero, Mariano Monzó, Carmen Muñoz-García, Jose Domingo-Domenech, Alfons Navarro, Carlos Conill, Marc Campayo, Jose A. Bombí. (2008) Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. Journal of Surgical Oncology 98:2, 130-134
CrossRef329
G. F. Tillman, T. Pawlicki, A. C. Koong, K. A. Goodman. (2008) Preoperative versus postoperative radiotherapy for locally advanced gastroesophageal junction and proximal gastric cancers: a comparison of normal tissue radiation doses. Diseases of the Esophagus 21:5, 437-444
CrossRef330
Sasako, Mitsuru, Sano, Takeshi, Yamamoto, Seiichiro, Kurokawa, Yukinori, Nashimoto, Atsushi, Kurita, Akira, Hiratsuka, Masahiro, Tsujinaka, Toshimasa, Kinoshita, Taira, Arai, Kuniyoshi, Yamamura, Yoshitaka, Okajima, Kunio, . (2008) D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer. New England Journal of Medicine 359:5, 453-462
Full Text331
Valerie K. Reed, Sunil Krishnan, Paul F. Mansfield, Priya R. Bhosale, Michelle Kim, Prajnan Das, Nora A. Janjan, Marc E. Delclos, Andrew M. Lowy, Barry W. Feig, Peter W.T. Pisters, Jaffer A. Ajani, Christopher H. Crane. (2008) Incidence, Natural History, and Patterns of Locoregional Recurrence in Gastric Cancer Patients Treated With Preoperative Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 71:3, 741-747
CrossRef332
C N. Leong, Hans T. Chung, K M. Lee, Thomas P. Shakespeare, Rahul K. Mukherjee, L C. Wong, Jiade J. Lu, J Tey, Robert Lim, J B.Y. So, Michael F. Back. (2008) Outcomes of Adjuvant Chemoradiotherapy After a Radical Gastrectomy and a D2 Node Dissection for Gastric Adenocarcinoma. The Cancer Journal 14:4, 269-275
CrossRef333
David Kelsen. (2008) S-1 adjuvant chemotherapy for advanced gastric cancer. Nature Clinical Practice Oncology 5:7, 370-371
CrossRef334
Luo Tianhang, Fang Guoen, Bi Jianwei, Ma Liye. (2008) The Effect of Perineural Invasion on Overall Survival in Patients with Gastric Carcinoma. Journal of Gastrointestinal Surgery 12:7, 1263-1267
CrossRef335
Hans T. Chung, Brian Lee, Eileen Park, Jiade J. Lu, Ping Xia. (2008) Can All Centers Plan Intensity-Modulated Radiotherapy (IMRT) Effectively? An External Audit of Dosimetric Comparisons Between Three-Dimensional Conformal Radiotherapy and IMRT for Adjuvant Chemoradiation for Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 71:4, 1167-1174
CrossRef336
T. Liakakos, D. Roukos. (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surgical Endoscopy 22:6, 1553-1555
CrossRef337
Neal W. Wilkinson, James Howe, Greer Gay, Lina Patel-Parekh, Carol Scott-Conner, John Donohue. (2008) Differences in the Pattern of Presentation and Treatment of Proximal and Distal Gastric Cancer: Results of the 2001 Gastric Patient Care Evaluation. Annals of Surgical Oncology 15:6, 1644-1650
CrossRef338
Mitsuru Sasako. (2008) Surgery and adjuvant chemotherapy. International Journal of Clinical Oncology 13:3, 193-195
CrossRef339
Theodore Liakakos, Nikolaos Xeropotamos, Dimosthenis Ziogas, Dimitrios Roukos. (2008) EGFR as a Prognostic Marker for Gastric Cancer. World Journal of Surgery 32:6, 1225-1226
CrossRef340
Michael Fatouros, Dimosthenis Ziogas. (2008) Controversy in the Treatment of Gastric Cancer. Annals of Surgical Oncology 15:6, 1795-1797
CrossRef341
Yixing Jiang, Eric T Kimchi, Alberto J Montero, Kevin F Staveley-O’Carroll, Jaffer A Ajani. (2008) Upper gastrointestinal tumors: current status and future perspectives. Expert Review of Anticancer Therapy 8:6, 975-991
CrossRef342
T. Liakakos. (2008) Minimal Residual Disease in Breast Cancer: Can It Be Used as a Prognostic Marker?. Annals of Surgical Oncology 15:6, 1793-1794
CrossRef343
J Wydmanski, BK Mohanti. (2008) An appraisal of radiation therapy techniques for adjuvant and neoadjuvant therapy in gastric cancer. Journal of Radiotherapy in Practice 7:02,
CrossRef344
Heerim Nam, Do Hoon Lim, Sung Kim, Won Ki Kang, Tae Sung Sohn, Jae Hyung Noh, Yong Il Kim, Chan Hyung Park, Chul Keun Park, Yong Chan Ahn, Seung Jae Huh. (2008) A New Suggestion for the Radiation Target Volume After a Subtotal Gastrectomy in Patients With Stomach Cancer. International Journal of Radiation Oncology*Biology*Physics 71:2, 448-455
CrossRef345
Evangelos Briasoulis, Dimosthenis Ziogas, Michael Fatouros. (2008) Prophylactic Surgery in the Complex Decision-Making Management of BRCA Mutation Carriers. Annals of Surgical Oncology 15:6, 1788-1790
CrossRef346
Pascal Artru, Gérard Lledo. (2008) Traitement Adjuvant Oral Du Cancer Gastrique: Une Grande Première Au Pays Du Soleil Levant!. Acta Endoscopica 38:2, 196-196
CrossRef347
E. Wöll. (2008) Perioperative therapy in gastric cancer. memo - Magazine of European Medical Oncology 1:2, 71-73
CrossRef348
Michael Fatouros, Georgios Baltogiannis. (2008) To the Editor: The Role of Prophylactic Surgery in Cancer Prevention. World Journal of Surgery 32:6, 1219-1220
CrossRef349
Nikhil I. Khushalani. (2008) Cancer of the Esophagus and Stomach. Mayo Clinic Proceedings 83:6, 712-722
CrossRef350
N. I. Khushalani. (2008) Cancer of the Esophagus and Stomach. Mayo Clinic Proceedings 83:6, 712-722
CrossRef351
C. Gravalos, A. Jimeno. (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of Oncology 19:9, 1523-1529
CrossRef352
David J. Sher, John W. Henson, Bindu Avutu, Fred H. Hochberg, Tracy T. Batchelor, Robert L. Martuza, Fred G. Barker, Jay S. Loeffler, Arnab Chakravarti. (2008) The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. Journal of Neuro-Oncology 88:1, 43-50
CrossRef353
Takeshi Sano. (2008) Adjuvant and neoadjuvant therapy of gastric cancer: A comparison of three pivotal studies. Current Oncology Reports 10:3, 191-198
CrossRef354
Walter C. MacDonald, David A. Owen, Nhu Le. (2008) Chronic advanced gastric cancer: clinicopathologic analysis of survival data. Human Pathology 39:5, 641-649
CrossRef355
Yoshiro Saikawa, Tetsuro Kubota, Koshi Kumagai, Rieko Nakamura, Koichiro Kumai, Naoyuki Shigematsu, Atsushi Kubo, Masaki Kitajima, Yuko Kitagawa. (2008) Phase II Study of Chemoradiotherapy With S-1 and Low-Dose Cisplatin for Inoperable Advanced Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 71:1, 173-179
CrossRef356
Jeffrey J. Meyer, Brian G. Czito, Christopher G. Willett. (2008) Intensity-modulated radiation therapy for gastrointestinal tumors. Current Oncology Reports 10:3, 206-211
CrossRef357
Michelle M. Kim, Paul F. Mansfield, Prajnan Das, Nora A. Janjan, Brian D. Badgwell, Alexandria T. Phan, Marc E. Delclos, Dipen Maru, Jaffer A. Ajani, Christopher H. Crane, Sunil Krishnan. (2008) Chemoradiation Therapy for Potentially Resectable Gastric Cancer: Clinical Outcomes Among Patients Who Do Not Undergo Planned Surgery. International Journal of Radiation Oncology*Biology*Physics 71:1, 167-172
CrossRef358
Theodore Liakakos, Dimitrios H. Roukos. (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer?. Surgical Endoscopy 22:5, 1402-1404
CrossRef359
Michael Fatouros, Dimosthenis Ziogas, Dimitrios H. Roukos. (2008) Outcomes of breast cancer patients with and without BRCA1/2 mutations. International Journal of Cancer 122:8, 1918-1919
CrossRef360
H. Wilke, N. Willich, H.-J. Meyer, M. Stahl. (2008) Neoadjuvante und perioperative Therapie des Magenkarzinoms. Der Onkologe 14:4, 370-380
CrossRef361
Toshimasa Tsujinaka, Kazumasa Fujitani, Motohira Hirao, Yukimori Kurokawa. (2008) Current status of chemoradiotherapy for gastric cancer in Japan. International Journal of Clinical Oncology 13:2, 117-120
CrossRef362
L. Meyer, K. Ridwelski, F. Meyer, I. Gastinger, H. Lippert. (2008) Qualitätssicherungsstudie zum Magenkarzinom in Deutschland. Der Onkologe 14:4, 396-402
CrossRef363
Iris Meier, Susanne Merkel, Thomas Papadopoulos, Rolf Sauer, Werner Hohenberger, Thomas B. Brunner. (2008) Adenocarcinoma of the Esophagogastric Junction: The Pattern of Metastatic Lymph Node Dissemination as a Rationale for Elective Lymphatic Target Volume Definition. International Journal of Radiation Oncology*Biology*Physics 70:5, 1408-1417
CrossRef364
Theodore Liakakos. (2008) Laparoscopic Gastrectomy: Feasibility, Safety and Efficacy. Annals of Surgical Oncology 15:4, 1249-1250
CrossRef365
B. Topal, E. Leys, N. Ectors, R. Aerts, F. Penninckx. (2008) Determinants of complications and adequacy of surgical resection in laparoscopic versus open total gastrectomy for adenocarcinoma. Surgical Endoscopy 22:4, 980-984
CrossRef366
European Union Network of Excellenc. (2008) Gastric cancer in Europe. British Journal of Surgery 95:4, 406-408
CrossRef367
Jae-Lyun Lee, Yoon-Koo Kang. (2008) Capecitabine in the treatment of advanced gastric cancer. Future Oncology 4:2, 179-198
CrossRef368
H. Harissis, M. Fatouros. (2008) Nodal Micrometastases Status—Will It Influence Decisions on Surgical and Adjuvant Treatment for Breast Cancer?. Annals of Surgical Oncology 15:4, 1256-1257
CrossRef369
E. Hanisch, D. Ziogas, D. Roukos, C. Hottenrott. (2008) Advances in Laparoscopic Gastrectomy Expand Clinical Use. Annals of Surgical Oncology 15:4, 1251-1252
CrossRef370
Dimosthenis Ziogas, Georgios Baltogiannis, Michael Fatouros, Dimitrios H. Roukos. (2008) Identifying and Preventing High-risk Gastric Cancer Individuals With CDH1 Mutations. Annals of Surgery 247:4, 714-715
CrossRef371
Theodore Liakakos, Dimitrios H. Roukos. (2008) More Controversy than Ever – Challenges and Promises Towards Personalized Treatment of Gastric Cancer. Annals of Surgical Oncology 15:4, 956-960
CrossRef372
F. Di Costanzo, S. Gasperoni, L. Manzione, G. Bisagni, R. Labianca, S. Bravi, E. Cortesi, P. Carlini, R. Bracci, S. Tomao, L. Messerini, A. Arcangeli, V. Torri, D. Bilancia, I. Floriani, M. Tonato, . (2008) Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC. JNCI Journal of the National Cancer Institute 100:6, 388-398
CrossRef373
A. Wu, J. Ji. (2008) Adjuvant Chemotherapy for Gastric Cancer or Not: A Dilemma?. JNCI Journal of the National Cancer Institute 100:6, 376-377
CrossRef374
Alexander J. Greenstein, Virginia R. Litle, Scott J. Swanson, Celia M. Divino, Stuart Packer, Juan P. Wisnivesky. (2008) Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer 112:6, 1239-1246
CrossRef375
Javier Gallego Plazas, Vanesa Pons Sanz. (2008) Towards an optimal treatment strategy for patients with oesophageal cancer. Clinical and Translational Oncology 10:3, 131-133
CrossRef376
E. Lykoudis, N. Xeropotamos, D. Ziogas, M. Fatouros. (2008) Breast Conservation Therapy: Multiple Reexcisions or Subcutaneous and Nipple-Sparing Mastectomy?. Annals of Surgical Oncology 15:3, 943-944
CrossRef377
John S. Moody, Stephen M. Sawrie, Kevin R. Kozak, John P. Plastaras, George Howard, James A. Bonner. (2008) Stage-Specific Survival Differences Associated with Postoperative Radiotherapy for Gastrointestinal Cancers. Journal of Gastrointestinal Cancer 39:1-4, 86-99
CrossRef378
Jolie Ringash, Stephen R. Smalley, Leonard L. Gunderson. (2008) Locoregional control remains a critical issue in gastric cancer. Gastric Cancer 11:1, 64-65
CrossRef379
Theodore Liakakos, Georgios Baltogiannis. (2008) Reducing Local Recurrence after Breast-Conserving Surgery for Breast Cancer. Annals of Surgical Oncology 15:3, 949-950
CrossRef380
Natalie G. Coburn, Ulrich Guller, Nancy N. Baxter, Alex Kiss, Jolie Ringash, Carol J. Swallow, Calvin H.L. Law. (2008) Adjuvant Therapy for Resected Gastric Cancer—Rapid, Yet Incomplete Adoption Following Results of Intergroup 0116 Trial. International Journal of Radiation Oncology*Biology*Physics 70:4, 1073-1080
CrossRef381
Heath B. Mackley, Jonathan S. Adelstein, Chandana A. Reddy, David J. Adelstein, Thomas W. Rice, Jerrold P. Saxton, Gregory M. M. Videtic. (2008) Choice of Radiotherapy Planning Modality Influences Toxicity in the Treatment of Locally Advanced Esophageal Cancer. Journal of Gastrointestinal Cancer 39:1-4, 130-137
CrossRef382
Eric D Tetzlaff, Putao Cen, Jaffer A Ajani. (2008) Emerging drugs in the treatment of advanced gastric cancer. Expert Opinion on Emerging Drugs 13:1, 135-144
CrossRef383
E. Samalin, M. Ychou. (2008) Le point sur les traitements adjuvants et néoadjuvants des adénocarcinomes œsogastriques. Oncologie 10:3, 175-181
CrossRef384
Liakakos Theodore. (2008) Reexcisions in Breast-Conserving Surgery for Breast Cancer: Can They Be Avoided?. Annals of Surgical Oncology 15:3, 945-946
CrossRef385
Oliver Drognitz, Karl Henne, Christian Weissenberger, Gregor Bruggmoser, Heike Göbel, Ulrich Theodor Hopt, Herrmann Frommhold, Günther Ruf. (2008) Long-Term Results After Intraoperative Radiation Therapy for Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 70:3, 715-721
CrossRef386
Aristotle Bamias, George Fountzilas, Michael Michael, Christos Konstantaras, Eleftheria Vrettou, Efstathios Eleftheriadis, Pavlos Papakostas, Konstantionos Papadimitriou, Nicholas Pavlidis, Nikos Xiros, Maria Bai. (2008) DCC and TS protein expression in resected gastric cancer: A Hellenic Cooperative Oncology Group Study. Central European Journal of Medicine 3:1, 29-39
CrossRef387
Natalie G. Coburn, Anand Govindarajan, Calvin H. L. Law, Ulrich Guller, Alex Kiss, Jolie Ringash, Carol J. Swallow, Nancy N. Baxter. (2008) Stage-Specific Effect of Adjuvant Therapy Following Gastric Cancer Resection: a Population-based Analysis of 4,041 Patients. Annals of Surgical Oncology 15:2, 500-507
CrossRef388
Andrew C. Chang, Hong Ji, Nancy J. Birkmeyer, Mark B. Orringer, John D. Birkmeyer. (2008) Outcomes After Transhiatal and Transthoracic Esophagectomy for Cancer. The Annals of Thoracic Surgery 85:2, 424-429
CrossRef389
Keiji Kato, Satoru Iida, Hiroyuki Uetake, Yoko Takagi, Toshiki Yamashita, Mikito Inokuchi, Hiroyuki Yamada, Kazuyuki Kojima, Kenichi Sugihara. (2008) MethylatedTMS1 andDAPK genes predict prognosis and response to chemotherapy in gastric cancer. International Journal of Cancer 122:3, 603-608
CrossRef390
Theodore Liakakos, Dimitrios H. Roukos. (2008) Does Lymphadenectomy Improve Survival of Patients with Solid Tumors?. Annals of Surgical Oncology 15:1, 385-385
CrossRef391
C.H. Park, K.Y. Song, S.N. Kim. (2008) Treatment results for gastric cancer surgery: 12 years’ experience at a single institute in Korea. European Journal of Surgical Oncology (EJSO) 34:1, 36-41
CrossRef392
Muhammad Wasif Saif, Amanda Sandoval. (2008) Atypical Hand-and-Foot syndrome in an African American Patient treated with Capecitabine with normal DPD activity: Is there an ethnic disparity?. Cutaneous and Ocular Toxicology 27:4, 311-315
CrossRef393
Eric Van Cutsem, Cornelius Van de Velde, Arnaud Roth, Florian Lordick, Claus-Henning Köhne, Stefano Cascinu, Matti Aapro. (2008) Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group. European Journal of Cancer 44:2, 182-194
CrossRef394
Dimosthenis Ziogas, Georgios Baltogiannis, Michael Fatouros. (2008) Lymphadenectomy in Surgical Oncology. Annals of Surgical Oncology 15:1, 386-387
CrossRef395
Theodore Liakakos. (2008) Peritoneal Recurrence for Gastric Cancer: Can It Be Prevented?. Annals of Surgical Oncology 15:1, 382-382
CrossRef396
Wendy A. Woodward, James D. Cox. 2008. Molecular Basis of Radiation Therapy. , 593-604.
CrossRef397
Dimitrios H Roukos. (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Review of Molecular Diagnostics 8:1, 29-39
CrossRef398
Edwin P.M. Jansen, Henk Boot, Mark P. Saunders, Tom D.L. Crosby, Ria Dubbelman, Harry Bartelink, Marcel Verheij, Annemieke Cats. (2007) A Phase I–II Study of Postoperative Capecitabine-Based Chemoradiotherapy in Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 69:5, 1424-1428
CrossRef399
T. Nakajima, T. Kinoshita, A. Nashimoto, M. Sairenji, T. Yamaguchi, J. Sakamoto, T. Fujiya, T. Inada, M. Sasako, Y. Ohashi, . (2007) Randomized controlled trial of adjuvant uracil–tegafurversus surgery alone for serosa-negative, locally advanced gastric cancer. British Journal of Surgery 94:12, 1468-1476
CrossRef400
Justin E. Bekelman, Michael J. Zelefsky, Thomas L. Jang, Ethan M. Basch, Deborah Schrag. (2007) Variation in Adherence to External Beam Radiotherapy Quality Measures Among Elderly Men With Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 69:5, 1456-1466
CrossRef401
Markus Moehler, P.R. Galle, I. Gockel, T. Junginger, H. Schmidberger. (2007) Multimodal treatment of gastric cancer. Best Practice & Research Clinical Gastroenterology 21:6, 965-981
CrossRef402
Lucy K. Helyer, Catherine O'Brien, Natalie G. Coburn, Carol J. Swallow. (2007) Surgeons' knowledge of quality indicators for gastric cancer surgery. Gastric Cancer 10:4, 205-214
CrossRef403
Francesco Fiorica, Francesco Cartei, Marco Enea, Anna Licata, Giuseppe Cabibbo, Barbara Carau, Alberto Liboni, Stefano Ursino, Calogero Cammà. (2007) The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data. Cancer Treatment Reviews 33:8, 729-740
CrossRef404
F. J. Lacueva, I. Oliver. (2007) Perioperative and adjuvant treatments for gastric cancer. Definitive new standards of care or are we still on the way?. Clinical and Translational Oncology 9:12, 747-748
CrossRef405
Stefan Welz, Thomas Hehr, Christian Kollmannsberger, Carsten Bokemeyer, Claus Belka, Wilfried Budach. (2007) Renal Toxicity of Adjuvant Chemoradiotherapy With Cisplatin in Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 69:5, 1429-1435
CrossRef406
G. Wichert, T. Seufferlein. (2007) Adjuvante Chemotherapie bei soliden Tumoren des Gastrointestinaltrakts. Der Internist 48:12, 1335-1342
CrossRef407
Pooja R. Patel, James C. Yao, Kenneth Hess, Isac Schnirer, Asif Rashid, Jaffer A. Ajani. (2007) Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer 110:10, 2186-2190
CrossRef408
Jaffer A. Ajani. (2007) Can We Understand the Clinical Biology of Gastric Cancer and Exploit it? May be, but It is a Challenge!. Annals of Surgical Oncology 14:12, 3290-3292
CrossRef409
Ylanga G. van der Geld, Suresh Senan, John R. van Sörnsen de Koste, Wilko F.A.R. Verbakel, Ben J. Slotman, Frank J. Lagerwaard. (2007) A Four-Dimensional CT-Based Evaluation of Techniques for Gastric Irradiation. International Journal of Radiation Oncology*Biology*Physics 69:3, 903-909
CrossRef410
Sakuramoto, Shinichi, Sasako, Mitsuru, Yamaguchi, Toshiharu, Kinoshita, Taira, Fujii, Masashi, Nashimoto, Atsushi, Furukawa, Hiroshi, Nakajima, Toshifusa, Ohashi, Yasuo, Imamura, Hiroshi, Higashino, Masayuki, Yamamura, Yoshitaka, Kurita, Akira, Arai, Kuniyoshi, . (2007) Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine. New England Journal of Medicine 357:18, 1810-1820
Full Text411
Cunningham, David, Chua, Yu Jo, . (2007) East Meets West in the Treatment of Gastric Cancer. New England Journal of Medicine 357:18, 1863-1865
Full Text412
Fumihiro Tanaka. (2007) UFT (Tegafur and Uracil) as Postoperative Adjuvant Chemotherapy for Solid Tumors (Carcinoma of the Lung, Stomach, Colon/Rectum, and Breast): Clinical Evidence, Mechanism of Action, and Future Direction. Surgery Today 37:11, 923-943
CrossRef413
Rebecca Kristeleit, Yujo Chua, David Cunningham. 2007. Multidisciplinary Team Management of Upper Gastrointestinal, Hepatic, Pancreatic, and Biliary Cancers. .
CrossRef414
Andrew P. Barbour, Nabil P. Rizk, Hans Gerdes, Manjit S. Bains, Valerie W. Rusch, Murray F. Brennan, Daniel G. Coit. (2007) Endoscopic Ultrasound Predicts Outcomes for Patients with Adenocarcinoma of the Gastroesophageal Junction. Journal of the American College of Surgeons 205:4, 593-601
CrossRef415
Daniel Coit. (2007) Adjuvant Therapy for Gastric Cancer. Journal of the American College of Surgeons 205:4, S54-S58
CrossRef416
Viacheslav Soyfer, Benjamin W. Corn, Alex Melamud, Shlomi Alani, Haim Tempelhof, Reuben Agai, Anat Shmueli, Arie Figer, Felix Kovner. (2007) Three-Dimensional Non–Coplanar Conformal Radiotherapy Yields Better Results Than Traditional Beam Arrangements for Adjuvant Treatment of Gastric Cancer. International Journal of Radiation Oncology*Biology*Physics 69:2, 364-369
CrossRef417
Vincenzo Valentini, Francesco Cellini. (2007) Radiotherapy in gastric cancer: a systematic review of literature and new perspectives. Expert Review of Anticancer Therapy 7:10, 1379-1393
CrossRef418
I. Oblak, V. Velenik, F. Anderluh, P. Strojan. (2007) Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia. European Journal of Surgical Oncology (EJSO) 33:8, 982-987
CrossRef419
Tristan D. Yan, Deborah Black, Paul H. Sugarbaker, Jacqui Zhu, Yutaka Yonemura, George Petrou, David L. Morris. (2007) A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer. Annals of Surgical Oncology 14:10, 2702-2713
CrossRef420
Yu Jo Chua, David Cunningham. (2007) The UK NCRI MAGIC Trial of Perioperative Chemotherapy in Resectable Gastric Cancer: Implications for Clinical Practice. Annals of Surgical Oncology 14:10, 2687-2690
CrossRef421
Evangelos Briasoulis, Michael Fatouros, Dimitrios H. Roukos. (2007) Level I Evidence in Support of Perioperative Chemotherapy for Operable Gastric Cancer: Sufficient for Wide Clinical Use?. Annals of Surgical Oncology 14:10, 2691-2695
CrossRef422
E P M Jansen, H Boot, R Dubbelman, H Bartelink, A Cats, M Verheij. (2007) Postoperative chemoradiotherapy in gastric cancer – a phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. British Journal of Cancer 97:6, 712-716
CrossRef423
N. Fazio, R. Biffi, G. Curigliano, K. Lorizzo, M. G. Zampino, F. de Braud, A. Chiappa, A. Roth, A. Goldhirsch. (2007) Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. JNCI Journal of the National Cancer Institute 99:17, 1345-1346
CrossRef424
S. Cascinu, M. Scartozzi, C. Barone, R. Labianca, A. Santoro, C. Carnaghi, G. D. Beretta, V. Catalano, S. Barni, L. Frontini. (2007) Response: Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. JNCI Journal of the National Cancer Institute 99:17, 1346-1347
CrossRef425
D.H. Koo, J.L. Lee, T.W. Kim, H.M. Chang, M.H. Ryu, J.H. Yook, S.T. Oh, B.S. Kim, J.S. Lee, Y.K. Kang. (2007) Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma. European Journal of Surgical Oncology (EJSO) 33:7, 843-848
CrossRef426
Rieko Nakamura, Yoshiro Saikawa, Koushi Kumagai, Tsuyoshi Kiyota, Masaki Ohashi, Masashi Yoshida, Tetsuro Kubota, Koichiro Kumai, Masaki Kitajima. (2007) A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1. International Journal of Clinical Oncology 12:4, 295-299
CrossRef427
David P. Kelsen. (2007) Systemic therapy for advanced gastric cancer: a review. Hematology/Oncology Clinics of North America 21, 18-25
CrossRef428
Christopher H. Crane, Gauri Varadhachary, Peter W.T. Pisters, Douglas B. Evans, Robert A. Wolff. (2007) Future Chemoradiation Strategies in Pancreatic Cancer. Seminars in Oncology 34:4, 335-346
CrossRef429
Yasuhiro Kodera, Seiji Ito, Michitaka Fujiwara, Yoshinari Mochizuki, Goro Nakayama, Norifumi Ohashi, Masahiko Koike, Yoshitaka Yamamura, Akimasa Nakao. (2007) Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: Correlation with drug sensitivity against 5-fluorouracil. Cancer Letters 252:2, 307-313
CrossRef430
Emmanuelle Samalin, Marc Ychou. (2007) Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts?. Current Opinion in Oncology 19:4, 384-389
CrossRef431
P. Khosravi Shahi, V. M. Díaz Muñoz de la Espada, P. García Alfonso, S. Encina García, Y. Izarzugaza Perón, J. L. Arranz Cozar, B. Hernández Marín, G. Pérez Manga. (2007) Management of gastric adenocarcinoma. Clinical and Translational Oncology 9:7, 438-442
CrossRef432
Kazuki Inaba, Yoichi Sakurai, Shinpei Furuta, Risaburo Sunagawa, Shuhei Tonomura, Yasuko Nakamura, Jun Isogaki, Ichiro Uyama, Yoshiyuki Komori, Ryoichi Kato, Tatsuo Banno. (2007) Hemorrhagic radiation gastritis after chemoradiation therapy for peritoneal lymph node metastasis of esophageal carcinoma successfully treated with repeated intraarterial steroid infusions. Esophagus 4:2, 67-72
CrossRef433
Scott A. Hundahl, Koen C.M.J. Peeters, E. Klein Kranenbarg, Henk Hartgrink, Cornelis J.H. van de Velde. (2007) Improved regional control and survival with “low Maruyama Index” surgery in gastric cancer: autopsy findings from the Dutch D1-D2 Trial. Gastric Cancer 10:2, 84-86
CrossRef434
Yasuhiro Kodera. (2007) The beginning of a new era: East meets West more comfortably regarding lymphadenectomy for gastric cancer — Japan will finally drop the surgery-alone arm in its pursuit of a multimodal treatment strategy. Gastric Cancer 10:2, 69-74
CrossRef435
Ming-Tsan Lin, Been-Ren Lin, Cheng-Chi Chang, Chia-Yu Chu, Hsiang-Ju Su, Szu-Ta Chen, Yung-Ming Jeng, Min-Liang Kuo. (2007) IL-6 induces AGS gastric cancer cell invasionvia activation of the c-Src/RhoA/ROCK signaling pathway. International Journal of Cancer 120:12, 2600-2608
CrossRef436
Eugene P. Kennedy, Charles J. Yeo. (2007) The case for routine use of adjuvant therapy in pancreatic cancer. Journal of Surgical Oncology 95:7, 597-603
CrossRef437
W.K. Tsang, S.F. Leung, S.K.W. Chiu, W.W.K. Yeung, E.K.W. Ng, W. Yeo, K.C. Lam, P.W.Y. Chiu, B.B.Y. Ma, W.H. Kwan, A.T.C. Chan†. (2007) Adjuvant Chemoradiation for Gastric Cancer: Experience in the Chinese Population. Clinical Oncology 19:5, 333-340
CrossRef438
Jeffrey A. Norton, Christine M. Ham, Jacques Van Dam, R Brooke Jeffrey, Teri A. Longacre, David G. Huntsman, Nicki Chun, Allison W. Kurian, James M. Ford. (2007) CDH1 Truncating Mutations in the E-Cadherin Gene. Annals of Surgery 245:6, 873-879
CrossRef439
Susan Jones-Bolin, Bruce Ruggeri. 2007. Orthotopic Models of Human Gastric Carcinoma in Nude Mice: Applications for Study of Tumor Growth and Progression. .
CrossRef440
Donald A Richards, Kristi A Boehm, Stephen P Anthony. (2007) Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions. Expert Opinion on Investigational Drugs 16:7, 1059-1068
CrossRef441
David Bentrem, Hans Gerdes, Laura Tang, Murray Brennan, Daniel Coit. (2007) Clinical Correlation of Endoscopic Ultrasonography with Pathologic Stage and Outcome in Patients Undergoing Curative Resection for Gastric Cancer. Annals of Surgical Oncology 14:6, 1853-1859
CrossRef442
A. M. Thompson, T. Rapson, F. J. Gilbert, K. G. M. Park, . (2007) Hospital volume does not influence long-term survival of patients undergoing surgery for oesophageal or gastric cancer. British Journal of Surgery 94:5, 578-584
CrossRef443
C. Bueno Muiño, J. Puente Vázquez, J. Sastre Valera, J. A. García-Sáenz, M. Martín, N. García Miralles, A. Sánchez-Pernaute, E. Díaz-Rubio. (2007) Pathological complete response following docetaxel-based neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma. Clinical and Translational Oncology 9:5, 335-338
CrossRef444
Kimmie Ng, Jeffrey A. Meyerhardt, Charles S. Fuchs. (2007) Adjuvant and Neoadjuvant Approaches in Gastric Cancer. The Cancer Journal 13:3, 168-174
CrossRef445
Giuseppe Toffoli, Erika Cecchin. (2007) Pharmacogenetics and stomach cancer: an update. Pharmacogenomics 8:5, 497-505
CrossRef446
Geoffrey Y. Ku, David H. Ilson. (2007) Esophageal Cancer: Adjuvant Therapy. The Cancer Journal 13:3, 162-167
CrossRef447
S. S. Ellenberg, W. Sun. (2007) Adjuvant Therapy for Gastric Cancer: How Negative Results Can Help Patients. JNCI Journal of the National Cancer Institute 99:8, 580-582
CrossRef448
S. Cascinu, R. Labianca, C. Barone, A. Santoro, C. Carnaghi, A. Cassano, G. D. Beretta, V. Catalano, O. Bertetto, S. Barni, L. Frontini, E. Aitini, S. Rota, V. Torri, I. Floriani. (2007) Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. JNCI Journal of the National Cancer Institute 99:8, 601-607
CrossRef449
Zsolt Káposztás, Katalin Kalmár, László Cseke, László Illényi, Dezső Kelemen, Örs Péter Horváth. (2007) Prognostic factors in the surgical treatment of gastric cancer – 10 years experience. Magyar Sebészet (Hungarian Journal of Surgery) 60:2, 71-78
CrossRef450
R. Krempien, M. W. Munter, W. Harms, J. Debus. (2007) Pancreatic cancer — Neoadjuvant therapy. The Chinese-German Journal of Clinical Oncology 6:2, 162-169
CrossRef451
W.J. Hyung, C. Song, J.H. Cheong, S.H. Choi, S.H. Noh. (2007) Factors influencing operation time of laparoscopy-assisted distal subtotal gastrectomy: Analysis of consecutive 100 initial cases. European Journal of Surgical Oncology (EJSO) 33:3, 314-319
CrossRef452
Andrew J. Graham, Fiona M. Shrive, William A. Ghali, Braden J. Manns, Sean C. Grondin, Richard J. Finley, Joanne Clifton. (2007) Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis. The Annals of Thoracic Surgery 83:4, 1257-1264
CrossRef453
Michael Findlay, David Storey, Val Gebski, Carol Hargreaves, Graham Cullingford, Michael Boyer, James Trotter, Stephen Archer, Andrew Davidson, Peter Johnston, Jennifer Yuen, Haryana Dhillon, Stephen Della-Fiorentina, Gary Richardson, Philip Truskett, David Goldstein, . (2007) A PILOT STUDY OF PREOPERATIVE AND POSTOPERATIVE CHEMOTHERAPY IN PATIENTS WITH OPERABLE GASTRIC CANCER: AUSTRALASIAN GASTROINTESTINAL TRIALS GROUP STUDY 9601. ANZ Journal of Surgery 77:4, 247-252
CrossRef454
Jun Ho Lee, Yong Hae Paik, Jong Seok Lee, Keun Won Ryu, Chan Gyoo Kim, Sook Ryeon Park, Young Woo Kim, Myeong Cherl Kook, Byung-ho Nam, Jae-Moon Bae. (2007) Abdominal Shape of Gastric Cancer Patients Influences Short-Term Surgical Outcomes. Annals of Surgical Oncology 14:4, 1288-1294
CrossRef455
Luis F. Oñate-Ocaña, Gonzalo Milán-Revollo, Vincenzo Aiello-Crocifoglio, José F. Carrillo, Dolores Gallardo-Rincón, Rocío Brom-Valladares, Roberto Herrera-Goepfert, Alfonso Dueñas-González. (2007) Treatment of the Adenocarcinoma of the Esophagogastric Junction at a Single Institution in Mexico. Annals of Surgical Oncology 14:4, 1439-1448
CrossRef456
Edwin P.M. Jansen, Mark P. Saunders, Henk Boot, Vera Oppedijk, Ria Dubbelman, Bridget Porritt, Annemieke Cats, Joep Stroom, Renato Valdés Olmos, Harry Bartelink, Marcel Verheij. (2007) Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. International Journal of Radiation Oncology*Biology*Physics 67:3, 781-785
CrossRef457
C. Schuhmacher, A. Novotny, K. Ott, M. Feith, J.R. Siewert. (2007) Lymphadenektomie bei Tumoren des oberen Gastrointestinaltraktes. Der Chirurg 78:3, 203-216
CrossRef458
T. Sano. (2007) Tailoring treatments for curable gastric cancer. British Journal of Surgery 94:3, 263-264
CrossRef459
Peter C. Enzinger, Jacqueline K. Benedetti, Jeffrey A. Meyerhardt, Sheryl McCoy, Scott A. Hundahl, John S. Macdonald, Charles S. Fuchs. (2007) Impact of Hospital Volume on Recurrence and Survival After Surgery for Gastric Cancer. Annals of Surgery 245:3, 426-434
CrossRef460
Andrew P. Barbour, Nabil P. Rizk, Mithat Gonen, Laura Tang, Manjit S. Bains, Valerie W. Rusch, Daniel G. Coit, Murray F. Brennan. (2007) Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome. Annals of Surgical Oncology 14:2, 306-316
CrossRef461
Roderich E. Schwarz, David D. Smith. (2007) Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Annals of Surgical Oncology 14:2, 317-328
CrossRef462
Jerzy Wydmański, Rafal Suwinski, Stanislaw Poltorak, Bogusław Maka, Leszek Miszczyk, Edyta Wolny, Grzegorz Bielaczyc, Aleksander Zajusz. (2007) The tolerance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase II study. Radiotherapy and Oncology 82:2, 132-136
CrossRef463
D.P. Cronin-Fenton, L. Sharp, A.-E. Carsin, H. Comber. (2007) Patterns of care and effects on mortality for cancers of the oesophagus and gastric cardia: A population-based study. European Journal of Cancer 43:3, 565-575
CrossRef464
Henk H Hartgrink, Cornelis JH van de Velde. (2007) Does perioperative chemotherapy improve survival in patients undergoing surgery for gastroesophageal cancer?. Nature Clinical Practice Oncology 4:2, 76-77
CrossRef465
Hasan Murshed, Kelly E. LeFave, Joseph A. Both. (2007) Clinical Fundamentals for Radiation Oncology Residents. Medical Physics 34:2, 786
CrossRef466
Christopher Jackson, Naureen Starling, Yu Jo Chua, David Cunningham. (2007) Pharmacotherapy for Oesophagogastric Cancer. Drugs 67:17, 2539-2556
CrossRef467
Bryan J. Schneider, Susan G. Urba. (2007) Preoperative Chemoradiation for the Treatment of Locoregional Esophageal Cancer: The Standard of Care?. Seminars in Radiation Oncology 17:1, 45-52
CrossRef468
Hayrullah Derici, Okay Nazli, Tugrul Tansug, Ali Dogan Bozdag, Nese Ekinci. (2007) Synchronous Primary Gastric Adenocarcinoma and Gastrointestinal Stromal Tumor. Chirurgische Gastroenterologie 23:1, 82-84
CrossRef469
Harold O. Douglass, Scott A. Hundahl, John S. Macdonald, Vijay P. Khatri. (2007) Gastric Cancer: D2 Dissection or Low Maruyama Index-Based Surgery—a Debate. Surgical Oncology Clinics of North America 16:1, 133-155
CrossRef470
Yasuhiro Kodera, Seiji Ito, Michitaka Fujiwara, Yoshinari Mochizuki, Norifumi Ohashi, Yuichi Ito, Goro Nakayama, Masahiko Koike, Yoshitaka Yamamura, Akimasa Nakao. (2006) In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. International Journal of Clinical Oncology 11:6, 449-453
CrossRef471
Pooja R. Rohatgi, James C. Yao, Kenneth Hess, Isac Schnirer, Asif Rashid, Paul F. Mansfield, Peter W. Pisters, Jaffer A. Ajani. (2006) Outcome of gastric cancer patients after successful gastrectomy. Cancer 107:11, 2576-2580
CrossRef472
R. C. Miller, M. G. Haddock, L. L. Gunderson, J. H. Donohue, V. F. Trastek, S. R. Alberts, C. Deschamps. (2006) Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas. Diseases of the Esophagus 19:6, 487-495
CrossRef473
Brian Knab, Carla Rash, Karl Farrey, Ashesh B. Jani. (2006) Intensity-modulated radiotherapy for neoadjuvant treatment of gastric cancer. Medical Dosimetry 31:4, 292-297
CrossRef474
K. P. McKian, R. C. Miller, S. D. Cassivi, A. Jatoi. (2006) Curing patients with locally advanced esophageal cancer: an update on multimodality therapy. Diseases of the Esophagus 19:6, 448-453
CrossRef475
L. Pemberton, J. Coote, L. Perry, V.S. Khoo, M.P. Saunders. (2006) Adjuvant Chemoradiotherapy for Gastric Carcinoma: Dosimetric Implications of Conventional Gastric Bed Irradiation and Toxicity. Clinical Oncology 18:9, 663-668
CrossRef476
Charles D. Blanke. (2006) ADDING PERIOPERATIVE CHEMOTHERAPY IMPROVES THE OUTCOME FROM SURGERY FOR POTENTIALLY CURABLE GASTROESOPHAGEAL CANCERS. Evidence-Based Gastroenterology 7:4, 91-92
CrossRef477
Natalie G. Coburn, Carol J. Swallow, Alex Kiss, Calvin Law. (2006) Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer 107:9, 2143-2151
CrossRef478
Pooja R. Rohatgi, Paul F. Mansfield, Christopher H. Crane, Tsung-Teh Wu, Punita K. Sunder, William A. Ross, Jeffrey S. Morris, Peter W. Pisters, Barry W. Feig, Leonard L. Gunderson, Jaffer A. Ajani. (2006) Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 107:7, 1475-1482
CrossRef479
Peter C Thuss-Patience, Albrecht Kretzschmar, Peter Reichardt. (2006) Docetaxel in the treatment of gastric cancer. Future Oncology 2:5, 603-620
CrossRef480
David H. Ilson. (2006) Cancer of the gastroesophageal junction: Current therapy options. Current Treatment Options in Oncology 7:5, 410-423
CrossRef481
(2006) Treatment of Gastric Cancer. New England Journal of Medicine 355:13, 1386-1388
Full Text482
Mansour S AL-MOUNDHRI, Bassim AL-BAHRANI, Ikram A BURNEY, Vadakeppat NIRMALA, Ali AL-MADHANI, Maryam AL-NABHANI, Valsa THOMAS, Shyam S GANGULY, Christopher S GRANT. (2006) The clinicopathological features, treatment and survival of gastric adenocarcinoma in Omani Arab patients. Asia-Pacific Journal of Clinical Oncology 2:3, 137-143
CrossRef483
Jun Ho Lee, Keun Won Ryu, Jin-Hee Lee, Sook Ryun Park, Chan Gyoo Kim, Myoung Cheorl Kook, Byung-Ho Nam, Young-Woo Kim, Jae-Moon Bae. (2006) Learning Curve for Total Gastrectomy with D2 Lymph Node Dissection: Cumulative Sum Analysis for Qualified Surgery. Annals of Surgical Oncology 13:9, 1175-1181
CrossRef484
Muhammad Wasif Saif, Lori Mattison, Tom Carollo, Hany Ezzeldin, Robert B. Diasio. (2006) Dihydropyrimidine dehydrogenase deficiency in an Indian population. Cancer Chemotherapy and Pharmacology 58:3, 396-401
CrossRef485
M Scartozzi, E Galizia, L Verdecchia, R Berardi, F Graziano, V Catalano, P Giordani, D Mari, R R Silva, C Marmorale, C Zingaretti, S Cascinu. (2006) Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. British Journal of Cancer 95:4, 445-449
CrossRef486
W. Yu. (2006) A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy. European Journal of Surgical Oncology (EJSO) 32:6, 655-660
CrossRef487
Vicente Tormo Ferrero, Francisco José Andreu Martínez, Rafael Cardenal Macía, Almudena Pomares Arias. (2006) Evaluation of the toxicity of the combined treatment of chemoradiotherapy, according to the scheme of Macdonald, after radical surgery in patients diagnosed of gastric cancer. Clinical and Translational Oncology 8:8, 611-615
CrossRef488
Felipe A. Calvo, Rosa M. Meirino, Roberto Orecchia. (2006) Intraoperative radiation therapy. Critical Reviews in Oncology/Hematology 59:2, 116-127
CrossRef489
Macdonald, John S., . (2006) Gastric Cancer — New Therapeutic Options. New England Journal of Medicine 355:1, 76-77
Full Text490
Cunningham, David, Allum, William H., Stenning, Sally P., Thompson, Jeremy N., Van de Velde, Cornelis J.H., Nicolson, Marianne, Scarffe, J. Howard, Lofts, Fiona J., Falk, Stephen J., Iveson, Timothy J., Smith, David B., Langley, Ruth E., Verma, Monica, Weeden, Simon, Chua, Yu Jo, . (2006) Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. New England Journal of Medicine 355:1, 11-20
Full Text491
Jean-Luc Van Laethem, Anne Demols. (2006) Adjuvant therapy in gastric and cardia cancer: should we irradiate?. Current Opinion in Oncology 18:4, 381-385
CrossRef492
Juan Manuel Miralles-Tena, Javier Escrig-Sos, David Martínez-Ramos, Vicente Ángel-Yepes, Carmen Villegas-Cánovas, Vicente Senent-Vizcaíno, José Luis Salvador-Sanchís. (2006) Cáncer gástrico: valoración probabilística ante un estadio ganglionar negativo y sus consecuencias. Cirugía Española 80:1, 32-37
CrossRef493
John Whiting, Takeshi Sano, Makoto Saka, Takeo Fukagawa, Hitoshi Katai, Mitsuru Sasako. (2006) Follow-up of gastric cancer: a review. Gastric Cancer 9:2, 74-81
CrossRef494
Tetsuro Kubota, Larry Weisenthal. (2006) Chemotherapy sensitivity and resistance testing: to be “standard” or to be individualized, that is the question. Gastric Cancer 9:2, 82-87
CrossRef495
Seiji Satoh, Suguru Hasegawa, Nobuhiro Ozaki, Hiroshi Okabe, Go Watanabe, Satoshi Nagayama, Masanori Fukushima, Arimichi Takabayashi, Yoshiharu Sakai. (2006) Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer 9:2, 129-135
CrossRef496
Yasuhiro Kodera. (2006) Neoadjuvant S-1 and cisplatin for gastric carcinoma: there will be more to come. Gastric Cancer 9:2, 72-73
CrossRef497
Yock Young Dan, J.B.Y. So, Khay Guan Yeoh. (2006) Endoscopic Screening for Gastric Cancer. Clinical Gastroenterology and Hepatology 4:6, 709-716
CrossRef498
Evangelos Briasoulis, Theodore Liakakos, Lefkothea Dova, Michael Fatouros, Pericles Tsekeris, Dimitrios H Roukos, Angelos M Kappas. (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Review of Anticancer Therapy 6:6, 931-939
CrossRef499
Thomas Ng, Thomas Dipetrillo, John Purviance, Howard Safran. (2006) Multimodality treatment of esophageal cancer: A review of the current status and future directions. Current Oncology Reports 8:3, 174-182
CrossRef500
H.-J. Ochel. (2006) A simple measure of reliability in clinical trials of surgical adjuvant radiotherapy. European Journal of Surgical Oncology (EJSO) 32:4, 395-399
CrossRef501
Chew-Wun Wu, Chao A Hsiung, Su-Shun Lo, Mao-Chin Hsieh, Jen-Hao Chen, Anna Fen-Yau Li, Wing-Yiu Lui, Jacqueline Whang-Peng. (2006) Nodal dissection for patients with gastric cancer: a randomised controlled trial. The Lancet Oncology 7:4, 309-315
CrossRef502
Kevin K Roggin, Mitchell C Posner. (2006) D3 or not D3 … that is not the question. The Lancet Oncology 7:4, 279-280
CrossRef503
D. Öfner. (2006) Gastric cancer. European Surgery 38:2, 89-93
CrossRef504
Michael Garofalo, Todd Flannery, William Regine. (2006) The case for adjuvant chemoradiation for pancreatic cancer. Best Practice & Research Clinical Gastroenterology 20:2, 403-416
CrossRef505
Feng-Ming (Spring) Kong, Lujun Zhao, James A. Hayman. (2006) The Role of Radiation Therapy in Thoracic Tumors. Hematology/Oncology Clinics of North America 20:2, 363-400
CrossRef506
Christopher H. Crane, Gauri Varadhachary, Robert A. Wolff, Peter W.T. Pisters, Douglas B. Evans. (2006) The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Practice & Research Clinical Gastroenterology 20:2, 365-382
CrossRef507
Christoph Oehler, I. Frank Ciernik. (2006) Radiation therapy and combined modality treatment of gastrointestinal carcinomas. Cancer Treatment Reviews 32:2, 119-138
CrossRef508
Amadeo Wals, Jorge Contreras, José Macías, Inmaculada Fortes, Daniel Rivas, Pedro González, Ismael Herruzo. (2006) Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP’s from the differential HDV of the organs at risk. Clinical & Translational Oncology 8:4, 271-278
CrossRef509
Arthur Y. Hung, Christopher A. Canning, Kamal M. Patel, John M. Holland, Lisa A. Kachnic. (2006) Radiation Therapy for Gastrointestinal Cancer. Hematology/Oncology Clinics of North America 20:2, 287-320
CrossRef510
Gennaro Galizia, Francesca Ferraraccio, Eva Lieto, Michele Orditura, Paolo Castellano, Vincenzo Imperatore, Giovanni La Manna, Margherita Pinto, Fortunato Ciardiello, Anna La Mura, Ferdinando De Vita. (2006) p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. Journal of Surgical Oncology 93:3, 241-252
CrossRef511
T. Etoh, M. Sasako, K. Ishikawa, H. Katai, T. Sano, T. Shimoda. (2006) Extranodal metastasis is an indicator of poor prognosis in patients with gastric carcinoma. British Journal of Surgery 93:3, 369-373
CrossRef512
Ann Driessen, Willy Landuyt, Sylvia Pastorekova, Johnny Moons, Laurence Goethals, Karin Haustermans, Philippe Nafteux, Freddy Penninckx, Karel Geboes, Toni Lerut, Nadine Ectors. (2006) Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas. Annals of Surgery 243:3, 334-340
CrossRef513
Stefania Beghelli, Giovanni de Manzoni, Stefano Barbi, Anna Tomezzoli, Franco Roviello, Carmela Di Gregorio, Carla Vindigni, Laura Bortesi, Alice Parisi, Luca Saragoni, Aldo Scarpa, Patrick S. Moore. (2006) Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery 139:3, 347-356
CrossRef514
J. S. Azagra, M. Goergen, V. Lens, J. F. Ibáñez-Aguirre, M. Schiltz, I. Siciliano. (2006) Present state of the Mini-Invasive Surgery (MIS) in esophageal and gastric cancer. Clinical and Translational Oncology 8:3, 173-177
CrossRef515
F. J. Lacueva, I. Oliver, D. Costa, R. Calpena. (2006) To perform or not D2 extended lymphadenectomy in patients with gastric cancer in the West. Effectiveness and limits. Clinical and Translational Oncology 8:3, 139-141
CrossRef516
Victor Archie, John Kauh, Dennie V. Jones, Victor Cruz, Martin S. Karpeh, Charles R. Thomas. (2006) Gastric cancer: Standards for the 21st century. Critical Reviews in Oncology/Hematology 57:2, 123-131
CrossRef517
R. Buzzoni, E. Bajetta, M. Di Bartolomeo, R. Miceli, E. Beretta, E. Ferrario, L. Mariani, . (2006) Pathological features as predictors of recurrence after radical resection of gastric cancer. British Journal of Surgery 93:2, 205-209
CrossRef518
C.T. Thomas, A. Ammar, J.J. Farrell, H. Elsaleh. (2006) Radiation Modifiers: Treatment Overview and Future Investigations. Hematology/Oncology Clinics of North America 20:1, 119-139
CrossRef519
Richard N Sullivan, Michael P N Findlay, John Zalcberg. (2006) Adjuvant and Neoadjuvant Therapy for Gastric Carcinoma. American Journal of Cancer 5:2, 111-121
CrossRef520
Anna D. Wagner, Paul M. Schneider, Wolfgang E. Fleig. (2006) The role of chemotherapy in patients with established gastric cancer. Best Practice & Research Clinical Gastroenterology 20:4, 789-799
CrossRef521
Hans-Dietrich Röher, Norbert M. Bösing. 2006. Magen – Duodenum. , 429-493.
CrossRef522
M.S. Al-Moundhri, B. Al-Bahrani, I.A. Burney, V. Nirmala, A. Al-Madhani, K. Al-Mawaly, M. Al-Nabhani, V. Thomas, S.S. Ganguly, C.S. Grant. (2006) The Prognostic Determinants of Gastric Cancer Treatment Outcome in Omani Arab Patients. Oncology 70:2, 90-96
CrossRef523
Alexander R. Novotny, Christoph Schuhmacher, Raymonde Busch, Michael W. Kattan, Murray F. Brennan, J??rg R??diger Siewert. (2006) Predicting Individual Survival After Gastric Cancer Resection. Annals of Surgery 243:1, 74-81
CrossRef524
Jean-François Aubry, Frédéric Beaulieu, Caroline Sévigny, Luc Beaulieu, Daniel Tremblay. (2006) Multiobjective optimization with a modified simulated annealing algorithm for external beam radiotherapy treatment planning. Medical Physics 33:12, 4718
CrossRef525
Prajnan Das, Jaffer A Ajani. (2005) Gastric and gastro-oesophageal cancer therapy. Expert Opinion on Pharmacotherapy 6:16, 2805-2812
CrossRef526
M.M. Mooney. (2005) Neoadjuvant and adjuvant chemotherapy for esophageal adenocarcinoma. Journal of Surgical Oncology 92:3, 230-238
CrossRef527
K.C.M.J. Peeters, S.A. Hundahl, E. Klein Kranenbarg, H. Hartgrink, C.J.H. Velde. (2005) Low Maruyama Index Surgery for Gastric Cancer: Blinded Reanalysis of the Dutch D1-D2 Trial. World Journal of Surgery 29:12, 1576-1584
CrossRef528
Santiago González-Moreno. (2005) Cirugía citorreductora y quimioterapia intraperitoneal perioperatoria para las neoplasias con diseminación peritoneal: ha llegado el momento. Cirugía Española 78:6, 341-343
CrossRef529
Trevor Leong. (2005) Chemotherapy and radiotherapy in the management of gastric cancer. Current Opinion in Gastroenterology 21:6, 673-678
CrossRef530
Ricardo J. Gonzalez, Paul F. Mansfield. (2005) Adjuvant and Neoadjuvant Therapy for Gastric Cancer. Surgical Clinics of North America 85:5, 1033-1051
CrossRef531
James Scolapio, Marcus Ferrone. 2005. Nutritional Management in the Patient with an Upper Gastrointestinal Cancer. .
CrossRef532
Shyh-Chuan Jwo, Rong-Nan Chien, Tzu-Chien Chao, Huang-Yang Chen, Chin-Yew Lin. (2005) Clinicopathological features, surgical management, and disease outcome of perforated gastric cancer. Journal of Surgical Oncology 91:4, 219-225
CrossRef533
Fania S Doekhie, Wilma E Mesker, J Han J. M. van Krieken, Niels F. M Kok, Henk H Hartgrink, Elma Klein Kranenbarg, Hein Putter, Peter J. K Kuppen, Hans J Tanke, Rob A. E. M Tollenaar, Cornelis J. H. van de Velde. (2005) Clinical Relevance of Occult Tumor Cells in Lymph Nodes From Gastric Cancer Patients. The American Journal of Surgical Pathology 29:9, 1135-1144
CrossRef534
Yasuhiro Kodera, Hayao Nakanishi, Seiji Ito, Yoshitaka Yamamura, Michitaka Fujiwara, Masahiko Koike, Kenji Hibi, Katsuki Ito, Masae Tatematsu, Akimasa Nakao. (2005) Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: detection of cytokeratin 20 mRNA in peritoneal washes, in addition to detection of carcinoembryonic antigen. Gastric Cancer 8:3, 142-148
CrossRef535
N. Birido, J.G. Geraghty. (2005) Quality control in breast cancer surgery. European Journal of Surgical Oncology (EJSO) 31:6, 577-586
CrossRef536
James Y. Tsai, David Iannitti, Anna Berkenblit, Paul Akerman, Ahmed Nadeem, Ritesh Rathore, David Harrington, Dean Roye, Thomas Miner, John M. Barnett, Christine Maia, Keith Stuart, Howard Safran. (2005) Phase I Study of Docetaxel, Capecitabine, and Carboplatin in Metastatic Esophagogastric Cancer. American Journal of Clinical Oncology 28:4, 329-333
CrossRef537
Gauri Varadhachary, Jaffer A Ajani. (2005) Preoperative and adjuvant therapies for upper gastrointestinal cancers. Expert Review of Anticancer Therapy 5:4, 719-725
CrossRef538
S.A. Hundahl, H.J. Wanebo. (2005) Changing gastric cancer treatment in the United States and the pursuit of quality. European Journal of Surgical Oncology (EJSO) 31:6, 605-615
CrossRef539
Raghuram P. Reddy, Michael J. Levy, Maurits J. Wiersema. (2005) Endoscopic Ultrasound for Luminal Malignancies. Gastrointestinal Endoscopy Clinics of North America 15:3, 399-429
CrossRef540
Joseph B. Zwischenberger, Brannon R. Hyde, Juan C. Escalon. (2005) What’s New in General Thoracic Surgery. Journal of the American College of Surgeons 201:1, 90-99
CrossRef541
Naoto Takahashi, H Kashiwagi, S Iwabuchi, Y Yamazaki, K Yanaga. (2005) Phase I Study of a Weekly Schedule of Fixed-Dose Paclitaxel and Escalating Doses of Cisplatin for Recurrent or Unresectable Gastric Cancer in Japan. American Journal of Clinical Oncology 28:3, 242-247
CrossRef542
Scott A. Hundahl. (2005) Eliminating and suppressing local-regional disease in gastric cancer. Journal of Surgical Oncology 90:3, 171-173
CrossRef543
G. Chong, D. Cunningham. (2005) Gastrointestinal cancer: recent developments in medical oncology. European Journal of Surgical Oncology (EJSO) 31:5, 453-460
CrossRef544
Howard Silberman. (2005) Perioperative adjunctive treatment in the management of operable gastric cancer. Journal of Surgical Oncology 90:3, 174-186
CrossRef545
C. Kollmannsberger, E. Gerber, W. Budach, C. Bokemeyer. (2005) Rolle der systemischen Therapie ± Radiotherapie beim resektablen Kardia-/Magenkarzinom. Der Onkologe 11:6, 650-657
CrossRef546
Vincenzo Catalano, Roberto Labianca, Giordano D. Beretta, Gemma Gatta, Filippo de Braud, Eric Van Cutsem. (2005) Gastric cancer. Critical Reviews in Oncology/Hematology 54:3, 209-241
CrossRef547
John S. Macdonald. (2005) Role of post-operative chemoradiation in resected gastric cancer. Journal of Surgical Oncology 90:3, 166-170
CrossRef548
Henk H. Hartgrink, Cornelis J.H. van de Velde. (2005) Status of extended lymph node dissection: Locoregional control is the only way to survive gastric cancer. Journal of Surgical Oncology 90:3, 153-165
CrossRef549
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin. (2005) Treatment for Pancreatic Cancer: Current Therapy and Continued Progress. Gastroenterology 128:6, 1642-1654
CrossRef550
David Bentrem, Andrew Wilton, Madhu Mazumdar, Murray Brennan, Daniel Coit. (2005) The Value of Peritoneal Cytology as a Preoperative Predictor in Patients With Gastric Carcinoma Undergoing a Curative Resection. Annals of Surgical Oncology 12:5, 347-353
CrossRef551
François Lacaine. (2005) Evidence-based Medicine in Surgical Decision Making. World Journal of Surgery 29:5, 588-591
CrossRef552
Anna Dorothea ADW Wagner, Winfried WG Grothe, Susanne Behl, Gerhard GK Kleber, Axel AG Grothey, Johannes Haerting, Wolfgang E. Fleig, Anna Dorothea ADW Wagner. 2005. Chemotherapy for advanced gastric cancer. .
CrossRef553
J. Ringash, S.J. Khaksar, A. Oza, J. Couture, B. Japp, M. Moore, L.L. Siu, D. Hedley, C. Swallow, S. Wong, B. Cummings, J. Kim, R. Wong, J. Brierley. (2005) Post-operative radiochemotherapy for gastric cancer: adoption and adaptation. Clinical Oncology 17:2, 91-95
CrossRef554
M Scartozzi, E Galizia, F Graziano, V Catalano, R Berardi, A M Baldelli, E Testa, D Mari, R R Silva, S Cascinu. (2005) Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. British Journal of Cancer 92:6, 1051-1054
CrossRef555
Oliver F. Bathe. (2005) Commentary. Journal of Surgical Oncology 89:4, 237-238
CrossRef556
Tawee Tanvetyanon, Joseph I. Clark, Steve C. Campbell, Simon S. Lo. (2005) Neoadjuvant Therapy: An Emerging Concept in Oncology. Southern Medical Journal 98:3, 338-344
CrossRef557
Koen C. M. J. Peeters, Michael W. Kattan, Henk H. Hartgrink, Elma Klein Kranenbarg, Martin S. Karpeh, Murray F. Brennan, Cornelis J. H. van de Velde. (2005) Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer 103:4, 702-707
CrossRef558
A. Gómez España, R. Serrano Blanch, E. Aranda Aguilar. (2005) Cáncer de esófago. Medicine - Programa de Formación Médica Continuada Acreditado 9:25, 1605-1612
CrossRef559
Dimitrios H Roukos, Angelos M Kappas. (2005) Perspectives in the treatment of gastric cancer. Nature Clinical Practice Oncology 2:2, 98-107
CrossRef560
R. Morales Chamorro, M.J. Méndez Vidal, E. Aranda Aguilar. (2005) Cáncer de estómago. Medicine - Programa de Formación Médica Continuada Acreditado 9:25, 1613-1620
CrossRef561
H J Kang, H M Chang, T W Kim, M-H Ryu, H J Sohn, J H Yook, S T Oh, B S Kim, J-S Lee, Y-K Kang. (2005) Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. British Journal of Cancer
CrossRef562
Joseph Fayçal, Christophe Bessaguet, Jean-Baptiste Nousbaum, Jean-Michel Cauvin, Franck Cholet, Karine Bideau, Michel Robaszkiewicz, Hervé Gouérou. (2005) Epidemiology and long term survival of gastric carcinoma in the French district of Finistère between 1984 and 1995. Gastroentérologie Clinique et Biologique 29:1, 23-32
CrossRef563
Laetitia Dahan, Dan Atlan, Olivier Bouché, Emmanuel Mitry, Pauline Ries, Pascal Artru, Karine Richard, Gérard Lledo, Tandat Nguyen, Philippe Rougier, Jean-François Seitz. (2005) Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen?. Gastroentérologie Clinique et Biologique 29:1, 11-15
CrossRef564
P. McCulloch, M. Eidi Niita, H. Kazi, J. J. Gama-Rodrigues. (2005) Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. British Journal of Surgery 92:1, 5-13
CrossRef565
Olivier Bouché. (2005) Comment améliorer le pronostic du cancer gastrique en France ?. Gastroentérologie Clinique et Biologique 29:1, 7-10
CrossRef566
Christian Manegold. (2005) Current Advancements in Hard-To-Treat Cancers. American Journal of Cancer 4:2, 105-113
CrossRef567
Sang Joon Shin, Sung Ho Chun, Kyeong Ok Kim, Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Sung Hwa Bae, Hun Mo Ryoo, Young Rok Do, Ki Young Kwon, Hong Suk Song. (2005) The Efficacy of Paclitaxel and Cisplatin Combination Chemotherapy for the Treatment of Metastatic or Recurrent Gastric Cancer: a Multicenter Phase II Study. The Korean Journal of Internal Medicine 20:2, 135
CrossRef568
Graeme Morgan, Robyn Ward, Michael Barton. (2004) The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clinical Oncology 16:8, 549-560
CrossRef569
Daniel G. Haller. (2004) Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers. Seminars in Oncology 31, 10-16
CrossRef570
Jason Chia-Hsien Cheng, Mei-Ching Liu, Stella Y. Tsai, Wei-Tse Fang, James Jer-Min Jian, Juei-Low Sung. (2004) Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer 101:9, 2126-2133
CrossRef571
Brett G. M. Hughes, Desmond Yip, Michael Chao, Peter Gibbs, Susan Carroll, David Goldstein, Bryan Burmeister, Christos Karapetis. (2004) Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience. ANZ Journal of Surgery 74:11, 951-956
CrossRef572
Michael D??Angelica, Mithat Gonen, Murray F. Brennan, Alan D. Turnbull, Manjit Bains, Martin S. Karpeh. (2004) Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma. Annals of Surgery 240:5, 808-816
CrossRef573
Clinton Snedegar, Bhaskar Banerjee. 2004. Current Perspectives in Gastric Adenocarcinoma. .
CrossRef574
W. Michael Korn. (2004) Prevention and management of early esophageal cancer. Current Treatment Options in Oncology 5:5, 405-416
CrossRef575
Giuseppe Toffoli, Erika Cecchin. (2004) Pharmacogenomics and stomach cancer. Pharmacogenomics 5:6, 627-641
CrossRef576
Geoff Delaney, Michael Barton, Susannah Jacob. (2004) Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma. Cancer 101:4, 657-670
CrossRef577
Trevor Leong. (2004) Evolving role of chemoradiation in the adjuvant treatment of gastric cancer. Expert Review of Anticancer Therapy 4:4, 585-594
CrossRef578
Gregory D Leonard, Eileen M.O Reilly. (2004) Post-operative chemotherapy improves disease-free survival, but not overall survival in people with oesophageal squamous cell carcinoma. Cancer Treatment Reviews 30:5, 473-477
CrossRef579
K.C.M.J. Peeters, C.J.H. van de Velde. (2004) Quality assurance of surgery in gastric and rectal cancer. Critical Reviews in Oncology/Hematology 51:2, 105-119
CrossRef580
Angelos M. Kappas, Michael Fatouros, Dimitrios H. Roukos. (2004) Is it Time to Change Surgical Strategy for Gastric Cancer in the United States?. Annals of Surgical Oncology 11:8, 727-730
CrossRef581
D H Lim, D Y Kim, M K Kang, Y I Kim, W K Kang, C K Park, S Kim, J H Noh, J W Joh, S H Choi, T S Sohn, J S Heo, C H Park, J O Park, J E Lee, Y J Park, H R Nam, W Park, Y C Ahn, S J Huh. (2004) Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view. British Journal of Cancer 91:1, 11-17
CrossRef582
Manish A. Shah, David P. Kelsen. (2004) Combined Modality Therapy of Esophageal Cancer: Changes in the Standard of Care?. Annals of Surgical Oncology 11:7, 641-643
CrossRef583
(2004) Chemotherapy for Pancreatic Cancer. New England Journal of Medicine 350:26, 2713-2715
Full Text584
Alexandria T. Phan, Jaffer A. Ajani. (2004) Gastric carcinoma. Current Oncology Reports 6:3, 192-198
CrossRef585
P Edwards, G R J C Blackshaw, W G Lewis, J D Barry, M C Allison, D R B Jones. (2004) Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma. British Journal of Cancer 90:10, 1888-1892
CrossRef586
H. Bora, D. Unsal, M. Akmansu. (2004) Results of chemoirradiation after curative resection of locally advanced gastric cancer. International Journal of Clinical Practice 58:5, 451-456
CrossRef587
Walter Lawrence. (2004) Gastric adenocarcinoma. Current Treatment Options in Gastroenterology 7:2, 149-157
CrossRef588
Burak Sakar, Hakan Karagol, Mahmut Gumus, Mert Basaran, Esra Kaytan, Andac Argon, Zeki Ustuner, Sevil E. Bavbek, Dursun Bugra, Faruk N. Aykan. (2004) Timing of Death From Tumor Recurrence After Curative Gastrectomy for Gastric Cancer. American Journal of Clinical Oncology 27:2, 205-209
CrossRef589
Michalis V Karamouzis, Athanasios G Papavassiliou. (2004) COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet?. Expert Opinion on Investigational Drugs 13:4, 359-372
CrossRef590
Abeezar I. Sarela, Murray F. Brennan, Martin S. Karpeh, David Klimstra, Kevin C. P. Conlon. (2004) Adenocarcinoma of the Duodenum: Importance of Accurate Lymph Node Staging and Similarity in Outcome to Gastric Cancer. Annals of Surgical Oncology 11:4, 380-386
CrossRef591
Jacques Chipponi, Michel Huguier, Denis Pezet, Nicolas Basso, Jean-Marie Hay, Pierre Quandalle, Daniel Jaeck, Pierre-Louis Fagniez, Alain Gainant. (2004) Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. The American Journal of Surgery 187:3, 440-445
CrossRef592
D. Nicolás Pérez, E. Quintero Carrión. (2004) Protocolo terapéutico del adenocarcinoma gástrico y de la unión esófago-gástrica. Medicine - Programa de Formación Médica Continuada Acreditado 9:2, 140-143
CrossRef593
Toshikazu Ushijima, Mitsuru Sasako. (2004) Focus on gastric cancer. Cancer Cell 5:2, 121-125
CrossRef594
Dimitrios H. Roukos. (2004) Early-Stage Gastric Cancer: A Highly Treatable Disease. Annals of Surgical Oncology 11:2, 127-129
CrossRef595
E. Quintero Carrión, D. Nicolás Pérez. (2004) Adenocarcinoma gástrico y de la unión esófago-gástrica. Medicine - Programa de Formación Médica Continuada Acreditado 9:2, 100-111
CrossRef596
Quyen M. Chu, Gazi Zibari, Richard H. Turnage. 2004. Gastric Surgery. , 152-156.
CrossRef597
Yoshiyuki Mori, Koji Kono, Yoshirou Matsumoto, Hideki Fujii, Tetsu Yamane, Masako Mitsumata, Wen-Tien Chen. (2004) The Expression of a Type II Transmembrane Serine Protease (Seprase) in Human Gastric Carcinoma. Oncology 67:5-6, 411-419
CrossRef598
Kazuhiko Mori, Kazuhiko Aoyagi, Tetsuya Ueda, Inaho Danjoh, Yasuhiro Tsubosa, Kazuyoshi Yanagihara, Yoshihiro Matsuno, Mitsuru Sasako, Hiromi Sakamoto, Ken-ichi Mafune, Michio Kaminishi, Teruhiko Yoshida, Masaaki Terada, Hiroki Sasaki. (2004) Highly specific marker genes for detecting minimal gastric cancer cells in cytology negative peritoneal washings. Biochemical and Biophysical Research Communications 313:4, 931-937
CrossRef599
Markus Moehler, Carl C. Schimanski, Ines Gockel, Theodor Junginger, Peter R. Galle. (2004) (Neo)adjuvant Strategies of Advanced Gastric Carcinoma: Time for a Change?. Digestive Diseases 22:4, 345-350
CrossRef600
Michael D. Kelly, Thomas N. Walsh. (2003) Adjuvant treatment for resectable adenocarcinoma of the oesophagus. ANZ Journal of Surgery 73:12, 976-978
CrossRef601
Aminah Jatoi. (2003) Aggressive multimodality therapy for patients with locally advanced esophageal cancer: is there a role for amifostine?. Seminars in Oncology 30, 72-75
CrossRef602
Thomas W Rice, David J Adelstein, Mark A Chidel, Lisa A Rybicki, Malcolm M DeCamp, Sudish C Murthy, Eugene H Blackstone. (2003) Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. The Journal of Thoracic and Cardiovascular Surgery 126:5, 1590-1596
CrossRef603
Koen C.M.J. Peeters, Cornelis J.H. van de Velde. (2003) Surgical quality assurance in breast, gastric and rectal cancer. Journal of Surgical Oncology 84:3, 107-112
CrossRef604
W. Scheithauer, E. Van Cutsem. (2003) The role of oxaliplatin in the management of upper gastrointestinal tract malignancies. Colorectal Disease 5:s3, 36-44
CrossRef605
Peter McCulloch, Marcelo Eidi Nita, Hussain Kazi, Joaquin Gama-Rodrigues, Peter McCulloch. 2003. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. .
CrossRef606
Katsuhiko Higuchi, Alexandria Phan, Jaffer A. Ajani. (2003) Gastric cancer: Advances in adjuvant and adjunct therapy. Current Treatment Options in Oncology 4:5, 413-419
CrossRef607
T Lerut, W Coosemans, G Decker, P De Leyn, N Ectors, S Fieuws, J Moons, P Nafteux, D Van Raemdonck. (2003) Extracapsular lymph node involvement is a negative prognostic factor in T3 adenocarcinoma of the distal esophagus and gastroesophageal junction. The Journal of Thoracic and Cardiovascular Surgery 126:4, 1121-1127
CrossRef608
Paul Okunieff, Raymond E. Meyn, Beverly A. Teicher, Charles R. Thomas, Laurie E. Gaspar, David Raben, Shankar Giri, Robert S. Lavey, Andrew T. Turrisi, Gregory P. Swanson, Stephen R. Smalley. (2003) Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG). American Journal of Clinical Oncology 26:5, 522-529
CrossRef609
M.F Back, S Premsenthil, C.J Wynne, T.P Shakespeare. (2003) Introducing the Intergroup 0116 Protocol of Adjuvant Chemo-radiotherapy in Gastric Cancer into Clinical Practice. Clinical Oncology 15:7, 378-382
CrossRef610
Katherine J.M Liu, Mark Loewen, Mary Jo Atten, Keith Millikan, Christopher Tebbit, Robert J Walter. (2003) The survival of stage III gastric cancer patients is affected by the number of lymph nodes removed. Surgery 134:4, 639-644
CrossRef611
Andreas Sendler, J Rüdiger Siewert. (2003) Individualizing therapy in gastric cancer. Expert Review of Anticancer Therapy 3:4, 457-470
CrossRef612
Henry Q Xiong, Leonard L Gunderson, James Yao, Jaffer A Ajani. (2003) Chemoradiation for resectable gastric cancer. The Lancet Oncology 4:8, 498-505
CrossRef613
Tyvin A. Rich, Robert Shepard. (2003) COX-2 Inhibitors as Radiation Sensitizers for Upper GI Tract Cancers: Esophagus, Stomach, and Pancreas. American Journal of Clinical Oncology 26:Supplement 2, S110-S113
CrossRef614
G. de Manzoni, C. Pedrazzani, F. Pasini, E. Durante, M. Gabbani, A. Grandinetti, A. Guglielmi, C. Griso, C. Cordiano. (2003) Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction. European Journal of Surgical Oncology (EJSO) 29:6, 506-510
CrossRef615
Peter Hohenberger, Stephan Gretschel. (2003) Gastic cancer. The Lancet 362:9380, 305-315
CrossRef616
Ross A Abrams. (2003) Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985?. International Journal of Radiation Oncology*Biology*Physics 56:4, 3-9
CrossRef617
Philip R Debruyne, Scott A Waldman, Stephanie Schulz. (2003) Pathological staging and therapy of oesophageal and gastric cancer. Expert Opinion on Pharmacotherapy 4:7, 1083-1096
CrossRef618
Christopher G Willett, Howard Safran, Ross A Abrams, William F Regine, Tyvin A Rich. (2003) Clinical research in pancreatic cancer: The Radiation Therapy Oncology Group trials. International Journal of Radiation Oncology*Biology*Physics 56:4, 31-37
CrossRef619
B Visser. (2003) Adjuvant and neoadjuvant therapy for esophageal cancer: a critical reappraisal. Surgical Oncology 12:1, 1-7
CrossRef620
John D Urschel, Hari Vasan. (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. The American Journal of Surgery 185:6, 538-543
CrossRef621
James Y. Tsai, Howard Safran. (2003) Status of treatment for advanced gastric carcinoma. Current Oncology Reports 5:3, 210-218
CrossRef622
Harold O. Douglass. (2003) Gastric Cancer: D2 All Over Again. Annals of Surgical Oncology 10:3, 206-207
CrossRef623
Arnaud D. Roth. (2003) Curative treatment of gastric cancer: towards a multidisciplinary approach?. Critical Reviews in Oncology/Hematology 46:1, 59-100
CrossRef624
Brian J. Davis, Thomas M. Pisansky, Bradley C. Leibovich. (2003) Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer. Current Opinion in Urology 13:2, 117-122
CrossRef625
Donato Nitti, Alberto Marchet, Matteo Olivieri, Alessandro Ambrosi, Roberto Mencarelli, Claudio Belluco, Mario Lise. (2003) Ratio Between Metastatic and Examined Lymph Nodes Is an Independent Prognostic Factor After D2 Resection for Gastric Cancer: Analysis of a Large European Monoinstitutional Experience. Annals of Surgical Oncology 10:9, 1077-1085
CrossRef626
Dimitrios H. Roukos, Evangelos Briasoulis, Konstantinos M. Michos, Moses Elisaf, Niki J. Agnantis, Angelos M. Kappas. (2003) Breast and Gastric Cancer: Comparing What We Learn. Annals of Surgical Oncology 10:1, 92-94
CrossRef627
Abeezar I. Sarela, Alan D. Turnbull, Daniel G. Coit, David Klimstra, Murray F. Brennan, Martin S. Karpeh. (2003) Accurate Lymph Node Staging is of Greater Prognostic Importance Than Subclassification of the T2 Category for Gastric Adenocarcinoma. Annals of Surgical Oncology 10:7, 783-791
CrossRef628
Jacques Wils. (2003) Perspectives in adjuvant gastric cancer therapy. Archive of oncology 11:3, 153-154
CrossRef629
Erkan Topuz, Mert Basaran, Pnar Saip, Adnan Aydiner, Andac Argon, Burak Sakar, Faruk Tas, Kazim Uygun, Dursun Bugra, N. Faruk Aykan. (2002) Adjuvant Intraperitoneal Chemotherapy With Cisplatinum, Mitoxantrone, 5-Fluorouracil, and Calcium Folinate in Patients With Gastric Cancer. American Journal of Clinical Oncology 25:6, 619-624
CrossRef630
Eric van Cutsem, Daniel Haller, Atsushi Ohtsu. (2002) The role of chemotherapy in the current treatment of gastric cancer. Gastric Cancer 5:S1, 17-22
CrossRef631
Tetsuo Taguchi, James Bishop. (2002) Challenge and opportunities in the treatment of gastric cancer. Gastric Cancer 5:S1, 1-3
CrossRef632
Dimitrios H. Roukos, Angelos M. Kappas. (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. Journal of Surgical Oncology 81:2, 59-62
CrossRef633
Jean-François Bosset, Mariette Mercier, Jean-Pierre Triboulet, Thierry Conroy, Jean-François Seitz. (2002) Surgical resection with and without chemotherapy in oesophageal cancer. The Lancet 360:9340, 1173-1174
CrossRef634
PETER F. CROOKES. (2002) Gastric Cancer. Clinical Obstetrics and Gynecology 45:3, 892-903
CrossRef635
Scott A. Hundahl. (2002) Surgical quality in trials of adjuvant cancer therapy. Journal of Surgical Oncology 80:4, 177-180
CrossRef636
S R Bramhall, M T Hallissey, J Whiting, J Scholefield, G Tierney, R C Stuart, R E Hawkins, P McCulloch, T Maughan, P D Brown, M Baillet, J W L Fielding. (2002) Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. British Journal of Cancer 86:12, 1864-1870
CrossRef637
David H. Ilson. (2002) New developments in the treatment of esophageal cancer. Current Oncology Reports 4:3, 213-221
CrossRef638
Manish A. Shah. (2002) Recent developments in the treatment of gastric carcinoma. Current Oncology Reports 4:3, 193-201
CrossRef639
T. Lehnert, B. Rudek, K. Buhl, M. Golling. (2002) Surgical therapy for loco-regional recurrence and distant metastasis of gastric cancer. European Journal of Surgical Oncology (EJSO) 28:4, 455-461
CrossRef640
Daniel G Haller, Jean-Louis Misset. (2002) Docetaxel in advanced gastric cancer. Anti-Cancer Drugs 13:5, 451-460
CrossRef641
James C. Yao, Jaffer A. Ajani. (2002) Adjuvant and preoperative chemotherapy for gastric cancer. Current Oncology Reports 4:3, 222-228
CrossRef642
J-H Choi, H-Y Lim, H J Joo, H S Kim, J W Yi, H C Kim, Y K Cho, M W Kim, K B Lee. (2002) Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. British Journal of Cancer 86:10, 1578-1585
CrossRef643
Roderich E. Schwarz, Kathryn Zagala-Nevarez. (2002) Recurrence patterns after radical gastrectomy for gastric cancer: Prognostic factors and implications for postoperative adjuvant therapy. Annals of Surgical Oncology 9:4, 394-400
CrossRef644
AD Wagner, W Grothe, S Behl, G Kleber, A Grothey, J Haerting, WE Fleig. 2002. Chemotherapy for advanced gastric cancer. .
CrossRef645
Dimitrios H. Roukos. (2002) Adjuvant chemoradiotherapy in gastric cancer: Wave goodbye to extensive surgery?. Annals of Surgical Oncology 9:3, 220-221
CrossRef646
Walter Lawrence. (2002) Our operative approach to cancer has been modified by scientific innovations: Is this true for gastrointestinal cancer?. Journal of Surgical Oncology 79:4, 205-208
CrossRef647
Scott A. Hundahl, John S. Macdonald, Jacqueline Benedetti, Thomas Fitzsimmons, . (2002) Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: The effect of undertreatment. Annals of Surgical Oncology 9:3, 278-286
CrossRef648
(2002) Scientific Surgery. British Journal of Surgery 89:2, 254-254
CrossRef649
(2002) Adjuvant Chemoradiotherapy for Gastric Cancer. New England Journal of Medicine 346:3, 210-211
Full Text
